carvedilol has been researched along with Blood Pressure, High in 313 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)." | 9.41 | A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021) |
| "Aim of the study was to assess effect of monotherapy with nebivolol, bisoprolol, carvedilol for 2 months on sexual function in men with arterial hypertension (AH)." | 9.17 | [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. ( Mustafaev, II; Nurmamedova, GS, 2013) |
| "Carvedilol, compared with enalapril, has a positive influence on LUTS related to BPH in patients with hypertension." | 9.17 | Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. ( Gaciong, Z; Judycki, J; Korecki, J; Lewandowski, J; Możeńska, O; Rogowski, K; Sieczych, A; Sinski, M; Symonides, B, 2013) |
| "The authors hypothesized that carvedilol controlled-release plus lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than hydrochlorothiazide plus lisinopril combination therapy (H+L) in obese patients with hypertension." | 9.16 | Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. ( Bank, AJ; Gonzalez-Campoy, JM; Katz, H; Kelly, AS; Metzig, AM; Rudser, KD; Thalin, M, 2012) |
| "We aimed to compare the effects of two beta-blockers (metoprolol and carvedilol) on the lipid profiles of hyperthyroid patients with hypertension." | 9.16 | The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism. ( Eren, MA; Ozbilen, S; Sabuncu, T; Turan, MN, 2012) |
| "The aim of this study was to compare nifedipine and carvedilol in the treatment of de novo arterial hypertension after orthotopic liver transplantation (OLT)." | 9.13 | Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. ( Angeli, P; Boccagni, P; Cillo, U; Fasolato, S; Frigo, AC; Galioto, A; Gatta, A; Semplicini, A; Sticca, A; Zanus, G, 2008) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 9.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "Carvedilol is indicated for the treatment of essential hypertension and mild-to-severe chronic heart failure, as well as the reduction of cardiovascular mortality in clinically stable post-myocardial infarction patients with left ventricular dysfunction." | 9.12 | Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. ( Baidoo, CA; Boyle, D; Campanile, AM; Danoff, TM; Harter, AH; Henderson, LS; Tenero, DM, 2006) |
| "Carvedilol is a beta1-, beta2-, and alpha1-adrenergic blocker that is approved for the treatment of hypertension." | 9.12 | Controlled-release carvedilol in the treatment of essential hypertension. ( Bakris, GL; Fleck, R; Iyengar, M; Sica, DA; Tarka, EA; Weber, MA, 2006) |
| "To compare the effects of carvedilol and propranolol on oxidative stress in leukocytes and C-reactive protein levels in patients with hypertension." | 9.11 | Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. ( Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J, 2004) |
| "Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension." | 9.11 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Oakes, R; Phillips, RA; Raskin, P; Wright, JT, 2004) |
| "The purpose of this pilot study was to test whether carvedilol has a protective effect against oxidative deoxyribonucleic acid (DNA) damage in human hypertension in vivo." | 9.11 | Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study. ( Cheong, SS; Choi, YS; Kim, JU; Lee, J; Lee, M; Song, KI, 2005) |
| "To study a hypotensive activity of carvedilol (dilatrend, Beringer Mannheim GMBH), its influence on 24-h profile of arterial pressure (AP), baroreceptor control of BP and vegetative regulation of the heart in elderly patients with mild and moderate arterial hypertension (AH)." | 9.09 | [Clinico-functional evaluation of hypotensive effect of carvedilol in elderly patients with mild and moderate arterial hypertension]. ( Bobyleva, MV; Gel'tser, BI; Khitrina, VV; Khludeeva, EA; Kotel'nikov, VN; Volkonskaia, OG, 2001) |
| "To compare the efficacy of native carvedilol(Cv) with native atenolol(At), we treated 80 cases of essential hypertension(stage I-II) for 4 weeks, using both open-test and double blind randomized imitative methods." | 9.09 | [Efficacy of native carvedilol in patients with essential hypertension]. ( Jia, Z; Lin, S; Peng, Y; Yang, T; Zhang, Z, 1999) |
| "To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension." | 9.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "To compare the effects of the ACE inhibitor perindopril and the beta-blocker carvedilol on blood pressure and endothelial functions in NIDDM patients with hypertension." | 9.08 | Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. ( Acampora, R; Coppola, L; D'Onofrio, F; Giugliano, D; Giunta, R; Marfella, R, 1998) |
| " The aim of this study was to compare the safety and antihypertensive efficacy of 25 to 50 mg carvedilol once daily with 50 to 100 mg atenolol once daily in patients with mild to moderate essential hypertension." | 9.07 | Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. ( Ruilope, LM, 1994) |
| "In a randomized, double-blind study oral doses of 50 mg carvedilol (Dilatrend) were compared with 40 mg propranolol in 16 male patients with coronary heart disease, CHD [12 without significant stenoses following percutaneous transluminal coronary angioplasty (PTCA), 4 with multivessel disease]." | 9.07 | Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. ( Wendt, T, 1992) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 9.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| "The safety and tolerability of carvedilol, a new antihypertensive agent with the combined pharmacological activities of beta-blockade and vasodilation, and of nifedipine were investigated in patients with essential hypertension and non-insulin-dependent (type II) diabetes mellitus." | 9.07 | Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. ( Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL, 1992) |
| "Carvedilol is a novel treatment for hypertension, having a balanced pharmacology of vasodilation and beta-receptor blockade." | 9.07 | A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. ( Ball, SG; Dixon, S; Hall, S; Hallman, RJ; Harvey, RE; Prescott, RI, 1991) |
| "The acute haemodynamic effect of carvedilol, a new non-selective beta-receptor blocker with vasodilating effect, was examined at rest supine and sitting and during 100 W bicycle exercise in 18 patients (mean age 44 years) with essential hypertension." | 9.07 | Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. ( Lund-Johansen, P; Omvik, P, 1991) |
| "A multicenter, randomized, double-blind, parallel-group trial of 8 weeks' duration was designed to compare the efficacy and safety of once-daily carvedilol with that of twice-daily labetalol in patients with essential hypertension." | 9.06 | Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. ( Bussiere, JL; Durier, P; Gayet, JL; Ollivier, JP, 1990) |
| "In an open clinical study, long-term efficacy and safety of carvedilol were investigated in 154 patients with essential hypertension WHO I-II and diastolic blood pressure (BP) between 95 and 115 mm Hg over a period of 1 year." | 9.06 | Efficacy and safety of carvedilol in the treatment of hypertension. ( Glocke, M; Schnurr, E; Widmann, L, 1987) |
| "The effect of once daily low-dose carvedilol on circadian variations of blood pressure (BP) was studied in Japanese patients with mild or moderate essential hypertension." | 9.06 | The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. ( Goto, Y; Iimura, O; Ikeda, M; Ishii, M; Kokubu, T; Kumahara, Y; Murakami, E; Ogihara, T; Takeda, T; Yoshinaga, K, 1987) |
| "A randomized, double-blind, placebo-controlled study was set up to study the effects of acute and chronic administration of carvedilol, a vasodilatory beta-blocker in essential hypertension." | 9.06 | Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. ( Block, P; Bossuyt, AM; Dupont, AG; Ingels, M; Jonckheer, MH; Piepsz, A; Six, RO; Taeymans, Y; Van der Niepen, P; Vanhaelst, L, 1987) |
| "Fifty milligrams of carvedilol and 100 mg atenolol were administered in a random order once a day for 2 months to 43 patients with mild to moderate hypertension, in a double-blind crossover study." | 9.06 | Carvedilol and atenolol once daily in the treatment of hypertension. ( Härkönen, R; Hilden, M; Icen, R; Kohvakka, A; Linna, M; Lukkala, K; Luurila, OJ; Sillanpää, J; Vänskä, O, 1989) |
| "Carvedilol is a novel, multiple-action cardiovascular drug that is currently approved in many countries for the treatment of hypertension." | 8.79 | Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1997) |
| "Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction." | 7.91 | Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019) |
| "Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation." | 7.83 | Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. ( Akçay, M; Aslan, AN; Baştuğ, S; Bozkurt, E; Durmaz, T; Sari, C; Sari, SÖ, 2016) |
| "A case of probable carvedilol-induced thrombocytopenia is reported." | 7.79 | Probable carvedilol-induced thrombocytopenia. ( Aggarwal, A; Alex, S; Cho, A; Chretien, KC, 2013) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 7.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "Aim of the study was to elucidate peculiarities of influence of carvedilol on 24-hour blood pressure (BP) profiles and changes of parameters of cerebral perfusion in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus." | 7.74 | [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus]. ( Belokopytova, NV; Efimova, IIu; Fal'kovskaia, AIu; Mordovin, VF, 2007) |
| "The aims of this study were to examine whether combined blockade of alpha(1) and beta-adrenoceptors with carvedilol postweaning affected the development of hypertension and renal vascular narrowing in spontaneously hypertensive rats (SHR), and whether these effects on pressure and renal vascular changes persisted after treatment withdrawal." | 7.72 | Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing. ( Anderson, WP; Boesen, EI; Denton, KM; Kett, MM, 2004) |
| "Carvedilol, a chiral compound possessing nonselective beta- and alpha1-blocking activity, is used for the treatment of hypertension and congestive heart failure (CHF)." | 7.70 | The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ( Boyle, DA; Gehr, TW; Qian, Y; Shusterman, NH; Sica, DA; Tenero, DM, 1999) |
| "The effects of carvedilol, a nonselective beta-blocker with peripheral vasodilator action, on left ventricular function and mass in essential hypertension were studied in 14 patients with diastolic filling abnormalities." | 7.68 | Effect of carvedilol on left ventricular function and mass in hypertension. ( Richardson, PJ; Why, HJ, 1992) |
| "Possible counterregulatory neurohumoral and hemodynamic responses to carvedilol (a new vasodilating nonselective beta-receptor blocker) were studied in 19 men with essential hypertension (age range, 34-59 years; mean age, 44 years)." | 7.68 | Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise. ( Lund-Johansen, P; Myking, O; Omvik, P, 1992) |
| "We assessed the long-term effects of carvedilol on renal function in 10 patients with mild-to-moderate essential hypertension." | 7.68 | Effect of long-term carvedilol therapy on renal function in essential hypertension. ( Marumo, F; Tomita, K, 1992) |
| "The purpose of this study was to investigate the effect of carvedilol on serum lipids in patients with mild-to-moderate essential hypertension." | 7.68 | Effects of carvedilol on serum lipids in patients with essential hypertension. ( Fusegawa, Y; Goto, Y; Homma, Y; Iori, S; Mikami, M; Nakaya, N; Tamachi, H; Yamazaki, A, 1991) |
| "The efficacy, safety, and pharmacokinetics of carvedilol were investigated in an open trial performed on six patients with hypertension and chronic renal failure requiring hemodialysis." | 7.68 | Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. ( Kaifu, Y; Masumura, H; Miki, S; Yuasa, S, 1991) |
| "The effects of a beta-blocker, carvedilol, on peripheral hemodynamics and hemorheologic parameters were evaluated in 11 geriatric patients with essential hypertension [3 men and 8 women aged 62-79 years (mean, 68." | 7.68 | Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension. ( Akedo, Y; Kaku, S; Nagakawa, Y; Orimo, H, 1990) |
| "We studied the effects of oral carvedilol (20 mg/day) on cerebral blood flow (CBF) and CBF autoregulation in ten previous stroke patients with hypertension." | 7.68 | Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. ( Kuriyama, Y; Kyougoku, I; Nakamura, M; Sawada, T, 1990) |
| "This study was performed to find the optimal dose of carvedilol, in terms of efficacy and safety, in Japanese patients with mild to moderate essential hypertension." | 7.67 | Dose-effect relationship of carvedilol in essential hypertension. An open study. ( Arakawa, K; Goto, Y; Iimura, O; Ishii, M; Kokubu, T; Kumahara, Y; Murakami, E; Ogihara, T; Takeda, T; Yoshinaga, K, 1988) |
| "Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure." | 6.77 | A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. ( Carbotta, S; Cittadini, A; Di Michele, S; Galzerano, D; Gaudio, C; Lama, D; Paolisso, G; Tedesco, MA; Tuccillo, B, 2012) |
| "In an open prospective 16-week study we carried out assessment of clinical efficacy, vaso- and cardioprotective properties of nonselective alpha and beta-adrenoblocker carvedilol used as monotherapy and in combination with nifedipine or as combination of these drugs with metformin and simvastatin." | 6.74 | [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. ( Eliseeva, IV; Gusakovskaia, LI; Matrosova, IB; Oleĭnikov, VE; Tomashevskaia, IuA, 2009) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 6.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period." | 6.72 | Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. ( Bakris, GL; Fleck, R; Iyengar, M; Sica, DA; Tarka, EA; Weber, MA, 2006) |
| "Nifedipine was effective in 4 of 18 patients, carvedilol, in 4 of 12 patients (22." | 6.71 | Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. ( Angeli, P; Boccagni, P; Burra, P; Carraro, A; Cillo, U; Fagiuoli, S; Fasolato, S; Galioto, A; Gatta, A; Guarda, S; Sartori, M; Semplicini, A; Sticca, A; Zanus, G, 2005) |
| "Carvedilol treatment also reduced the extent of in vivo LDL oxidation, as reflected by the decrease in antioxidized LDL autoantibody titer." | 6.68 | Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. ( Bellomo, G; Covini, D; Maggi, E; Marchesi, E; Negro, C; Perani, G, 1996) |
| "Carvedilol is a safe, efficient, once/day choice as monotherapy for mild to moderate essential hypertensive patients." | 6.67 | [Use of carvedilol compared to nifedipine in the treatment of mild and moderate essential arterial hypertension]. ( Dantas, M; Freitas, AF; Furtado, MR; Kohlmann, NE; Kohlmann, O; Plavnik, FL; Portela, JE; Spritzer, N; Spritzer, T, 1994) |
| " Dosing with 25 mg carvedilol once daily or 20 mg nifedipine SR twice daily resulted in mean peak reductions in supine blood pressure of 21/11 and 20/16 mm Hg, respectively, after 1 week of treatment with each respective monotherapy." | 6.67 | Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension. ( de Vries Robles, P; Juttmann, JR; Venuti, RP, 1992) |
| "The efficacy and safety of carvedilol, a beta-blocker with vasodilating properties, were compared at a dosage of 25 to 50 mg once daily with those of atenolol at a dosage of 50-100 mg once daily in a double-blind, randomized, parallel-group, multicenter study." | 6.67 | A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group. ( Young, PH, 1992) |
| "Carvedilol was generally well tolerated." | 6.67 | Clinical efficacy of carvedilol in severe hypertension. ( Arakawa, K; Goto, Y; Iimura, I; Ikeda, M; Ishii, M; Kamahara, Y; Kokubu, T; Ogihara, T; Takeda, T; Yoshinaga, K, 1991) |
| "Carvedilol was well tolerated; 2 patients experienced dizziness associated with postural hypotension after administration of the 50mg dose." | 6.66 | Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ( McPhillips, JJ; Patterson, D; Schwemer, GT; Scott, DI; Zinny, M, 1988) |
| "Carvedilol (BM 14190) is a new antihypertensive compound which combines beta-adrenoceptor blocking and precapillary vasodilating properties but is devoid of intrinsic sympathomimetic activity." | 6.65 | Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. ( Andrén, L; Eggertsen, R; Hansson, L; Sivertsson, R, 1984) |
| "Carvedilol is a vasodilating noncardioselective third-generation β-blocker, without the negative hemodynamic and metabolic effects of traditional β-blockers, which can be used as a cardioprotective agent." | 6.48 | Use of carvedilol in hypertension: an update. ( Egan, CG; Leonetti, G, 2012) |
| "Carvedilol is a novel antihypertensive agent." | 6.40 | Carvedilol in the treatment of hypertension--a review of the clinical data base. ( Hansson, L; Himmelmann, A, 1998) |
| "Carvedilol has been shown to be effective in systemic hypertension and coronary artery disease in patients with end-stage renal disease, on maintenance hemodialysis." | 6.18 | [Complex ventricular arrhythmias and carvedilol: efficacy in hemodialyzed uremic patients]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Tagliamonte, E, 1998) |
| "The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)." | 5.41 | A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021) |
| "Carvedilol showed enantioselective non-linear pharmacokinetic properties in both groups." | 5.36 | Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. ( Bernabeu, E; Bertera, F; Bramuglia, GF; Buontempo, F; Chiappetta, D; Di Verniero, CA; Höcht, C; Mayer, MA; Taira, CA, 2010) |
| " As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed." | 5.34 | [Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension]. ( Frese, T; Sandholzer, H, 2007) |
| "Carvedilol is a beta blocker with alpha-blocking activity and its profile of action is similar to that of a combination of a beta blocker and a diuretic." | 5.29 | Carvedilol in hypertension. ( Raftery, EB, 1993) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 5.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Carvedilol is a new beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade." | 5.29 | [Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension]. ( Barra, M; Gigli, G; Orlandi, S; Perocchio, M; Rosolen, GA; Sacchetti, R; Vallebona, A, 1996) |
| "Carvedilol is an effective antihypertensive agent, and the hemodynamic mode of action reflects alpha 1- and beta 1-blocking activities." | 5.28 | Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. ( Lund-Johansen, P; Nordrehaug, JE; Omvik, P; White, W, 1992) |
| " As a nonselective β-blocker, carvedilol is employed for treating many cardiovascular diseases in clinical practice, including hypertension, angina pectoris and heart failure, and also exhibit the effectiveness for glycemic control and insulin resistance." | 5.22 | Beneficial effects of carvedilol modulating potassium channels on the control of glucose. ( Li, XT, 2022) |
| "Aim of the study was to assess effect of monotherapy with nebivolol, bisoprolol, carvedilol for 2 months on sexual function in men with arterial hypertension (AH)." | 5.17 | [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. ( Mustafaev, II; Nurmamedova, GS, 2013) |
| "Carvedilol, compared with enalapril, has a positive influence on LUTS related to BPH in patients with hypertension." | 5.17 | Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. ( Gaciong, Z; Judycki, J; Korecki, J; Lewandowski, J; Możeńska, O; Rogowski, K; Sieczych, A; Sinski, M; Symonides, B, 2013) |
| "The aim of this study was to compare the effects of the new generation β-blocker anti-hypertensive drugs carvedilol and nebivolol on aortic elastic properties which are important indicators of hypertension-related morbidity and mortality." | 5.17 | Aortic elastic properties : effects of carvedilol versus nebivolol. ( Aktop, Z; Aydin, M; Cetiner, MA; Dogan, SM; Karabag, T; Sayin, MR, 2013) |
| "The authors hypothesized that carvedilol controlled-release plus lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than hydrochlorothiazide plus lisinopril combination therapy (H+L) in obese patients with hypertension." | 5.16 | Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. ( Bank, AJ; Gonzalez-Campoy, JM; Katz, H; Kelly, AS; Metzig, AM; Rudser, KD; Thalin, M, 2012) |
| "We aimed to compare the effects of two beta-blockers (metoprolol and carvedilol) on the lipid profiles of hyperthyroid patients with hypertension." | 5.16 | The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism. ( Eren, MA; Ozbilen, S; Sabuncu, T; Turan, MN, 2012) |
| "A prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily was performed among 25 hemodialysis participants with intradialytic hypertension." | 5.16 | Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. ( Inrig, JK; Kim, C; Povsic, TJ; Toto, R; Van Buren, P; Vongpatanasin, W, 2012) |
| "Carvedilol is an effective treatment in hypertension and chronic heart failure." | 5.15 | Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. ( Brockmöller, J; Gültepe, S; Meineke, I; Sehrt, D; Tzvetkov, M, 2011) |
| " Patients with essential hypertension and without significant concomitant cardiovascular disease were randomly assigned to controlled-release carvedilol, force-titrated to 80 mg (n=22), or atenolol, force-titrated to 100 mg (n=19); each was given once daily for 4 weeks." | 5.15 | Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). ( Ashfaq, U; Epstein, BJ; Johnson, JA; Lo, MC; Nichols, WW; Satish, P; Shah, NK; Smith, SM, 2011) |
| "Therapeutic efficiency of spirapryl and its combination with carvedilol in the treatment of diastolic cardiac insufficiency in patients with type 2 diabetes and essential arterial hypertension (AH)." | 5.14 | [Drug therapy of diastolic cardiac insufficiency in patients with type 2 diabetes and concomitant essential arterial hypertension]. ( Borovkov, NN; Iarkova, NA, 2009) |
| "The aim of this study was to compare nifedipine and carvedilol in the treatment of de novo arterial hypertension after orthotopic liver transplantation (OLT)." | 5.13 | Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. ( Angeli, P; Boccagni, P; Cillo, U; Fasolato, S; Frigo, AC; Galioto, A; Gatta, A; Semplicini, A; Sticca, A; Zanus, G, 2008) |
| "To study efficacy and safety of a preparation of carvedilol Acridilol (Akrikhin, Russia) in patients with mild and moderate arterial hypertension (AH) and obesity and/or compensated type 2 diabetes mellitus (DM)." | 5.13 | [First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)]. ( Deev, AD; Lukina, IuV; Martsevich, SIu; Oganov, RG; Shal'nova, SA, 2008) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 5.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "Carvedilol is indicated for the treatment of essential hypertension and mild-to-severe chronic heart failure, as well as the reduction of cardiovascular mortality in clinically stable post-myocardial infarction patients with left ventricular dysfunction." | 5.12 | Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. ( Baidoo, CA; Boyle, D; Campanile, AM; Danoff, TM; Harter, AH; Henderson, LS; Tenero, DM, 2006) |
| "Carvedilol is a beta1-, beta2-, and alpha1-adrenergic blocker that is approved for the treatment of hypertension." | 5.12 | Controlled-release carvedilol in the treatment of essential hypertension. ( Bakris, GL; Fleck, R; Iyengar, M; Sica, DA; Tarka, EA; Weber, MA, 2006) |
| "The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes." | 5.12 | beta-blocker use and diabetes symptom score: results from the GEMINI study. ( Anderson, KM; Bakris, GL; Bell, DS; Dalal, MR; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "In patients with diabetes and hypertension not taking insulin sensitizers, the use of metoprolol tartrate resulted in a worsening of insulin resistance, an effect not seen with carvedilol." | 5.12 | Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2007) |
| "Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months." | 5.12 | Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| " The current analysis of the Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial evaluates the effects of carvedilol and metoprolol tartrate on weight gain in patients with type 2 diabetes and hypertension." | 5.12 | Body weight changes with beta-blocker use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bangalore, S; Bell, DS; Fonseca, V; Holdbrook, FK; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "To compare the effects of carvedilol and propranolol on oxidative stress in leukocytes and C-reactive protein levels in patients with hypertension." | 5.11 | Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. ( Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J, 2004) |
| "Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension." | 5.11 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Oakes, R; Phillips, RA; Raskin, P; Wright, JT, 2004) |
| "The purpose of this pilot study was to test whether carvedilol has a protective effect against oxidative deoxyribonucleic acid (DNA) damage in human hypertension in vivo." | 5.11 | Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study. ( Cheong, SS; Choi, YS; Kim, JU; Lee, J; Lee, M; Song, KI, 2005) |
| "The hypothesis that left ventricular hypertrophy regression in hypertension relates to blood pressure (BP) control and to non-antihypertensive activity of some drugs was tested by comparing the effects of telmisartan and carvedilol on 24-h mean ambulatory BP and left ventricular mass (LVM) regression, measured using three-dimensional echocardiography (3-DECHO) and magnetic resonance imaging (MRI)." | 5.11 | Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. ( Breglio, R; Capogrosso, P; del Viscovo, L; Galzerano, A; Galzerano, D; Lama, D; Paolisso, G; Tammaro, P; Tuccillo, B, 2005) |
| " These tests were performed in healthy controls and in patients with essential hypertension (mean arterial pressure of 112+/-2 mmHg, age, 52+/-2 years; mean+/-SEM) within a washout period, and after long-term treatment with carvedilol and fosinopril, respectively." | 5.09 | Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. ( Estelberger, W; Holzer, H; Oettl, K; Reibnegger, G; Stoschitzky, K; Zitta, S; Zweiker, R, 2000) |
| "The aim of this study was to compare the effect of antihypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension." | 5.09 | Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. ( Corradi, L; Fogari, R; Marasi, G; Mugellini, A; Poletti, L; Zoppi, A, 2001) |
| "To study a hypotensive activity of carvedilol (dilatrend, Beringer Mannheim GMBH), its influence on 24-h profile of arterial pressure (AP), baroreceptor control of BP and vegetative regulation of the heart in elderly patients with mild and moderate arterial hypertension (AH)." | 5.09 | [Clinico-functional evaluation of hypotensive effect of carvedilol in elderly patients with mild and moderate arterial hypertension]. ( Bobyleva, MV; Gel'tser, BI; Khitrina, VV; Khludeeva, EA; Kotel'nikov, VN; Volkonskaia, OG, 2001) |
| "To compare the efficacy of native carvedilol(Cv) with native atenolol(At), we treated 80 cases of essential hypertension(stage I-II) for 4 weeks, using both open-test and double blind randomized imitative methods." | 5.09 | [Efficacy of native carvedilol in patients with essential hypertension]. ( Jia, Z; Lin, S; Peng, Y; Yang, T; Zhang, Z, 1999) |
| "Metoprolol and carvedilol are widely used in the treatment of hypertension, but no randomized comparison of their hemodynamic activity has been previously reported." | 5.08 | Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. ( Bohmeke, T; Taylor, SH; van der Does, R; Weber, K, 1996) |
| "Fifty-six patients with essential hypertension were recruited to study the metabolic effects of carvedilol, a non-selective beta-adrenoceptor-blocker with alpha 1-adrenoceptor blocking properties." | 5.08 | Metabolic effects of carvedilol in hypertensive patients. ( Andersson, PE; Lithell, H, 1997) |
| "To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension." | 5.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "To compare the effects of the ACE inhibitor perindopril and the beta-blocker carvedilol on blood pressure and endothelial functions in NIDDM patients with hypertension." | 5.08 | Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. ( Acampora, R; Coppola, L; D'Onofrio, F; Giugliano, D; Giunta, R; Marfella, R, 1998) |
| "To evaluate the preventive effect of nitrate tolerance, 24 patients with untreated hypertension were randomized to receive either carvedilol (10 mg twice a day [carvedilol group, n=8]), arotinolol (10 mg twice a day [arotinolol group, n=8]), or placebo (placebo group, n=8)." | 5.08 | Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| " The aim of this study was to compare the safety and antihypertensive efficacy of 25 to 50 mg carvedilol once daily with 50 to 100 mg atenolol once daily in patients with mild to moderate essential hypertension." | 5.07 | Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. ( Ruilope, LM, 1994) |
| "Data were obtained from a study of 15 men with moderate to severe essential hypertension who had been treated with a placebo followed by 6-8 months of carvedilol monotherapy (25-75 mg/day)." | 5.07 | Twenty-four-hour blood pressure load as a surrogate end-point in assessing antihypertensive therapy. ( Lund-Johansen, P; Omvik, P; White, WB, 1993) |
| "In a randomized, double-blind study oral doses of 50 mg carvedilol (Dilatrend) were compared with 40 mg propranolol in 16 male patients with coronary heart disease, CHD [12 without significant stenoses following percutaneous transluminal coronary angioplasty (PTCA), 4 with multivessel disease]." | 5.07 | Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. ( Wendt, T, 1992) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 5.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| "Forearm hemodynamics using pulsed Doppler flowmetry were studied in nine healthy volunteers and 12 patients with mild-to-moderate hypertension before and after acute oral administration of the beta-blocking and vasodilating agent carvedilol." | 5.07 | Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. ( Cournot, A; Duchier, J; Lim, C; Safar, M, 1992) |
| "The safety and tolerability of carvedilol, a new antihypertensive agent with the combined pharmacological activities of beta-blockade and vasodilation, and of nifedipine were investigated in patients with essential hypertension and non-insulin-dependent (type II) diabetes mellitus." | 5.07 | Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. ( Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL, 1992) |
| "Carvedilol is a novel treatment for hypertension, having a balanced pharmacology of vasodilation and beta-receptor blockade." | 5.07 | A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. ( Ball, SG; Dixon, S; Hall, S; Hallman, RJ; Harvey, RE; Prescott, RI, 1991) |
| "The acute haemodynamic effect of carvedilol, a new non-selective beta-receptor blocker with vasodilating effect, was examined at rest supine and sitting and during 100 W bicycle exercise in 18 patients (mean age 44 years) with essential hypertension." | 5.07 | Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. ( Lund-Johansen, P; Omvik, P, 1991) |
| "Carvedilol, a beta-blocking drug with vasodilator activity, has been used in 4 studies in 107 elderly patients with essential hypertension and has reduced blood pressure effectively." | 5.06 | The use of carvedilol in elderly hypertensive patients. ( Adam, W; Anderson, A; Cripps, J; Morgan, TO, 1990) |
| "Carvedilol has been shown to be effective and safe in patients with essential hypertension when given as monotherapy." | 5.06 | Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. ( Hörrmann, M; Machwirth, M; van der Does, R; Widmann, L, 1990) |
| ") as an adjunct to pre-existing hydrochlorothiazide (HCTZ) monotherapy in patients with mild to moderate hypertension [diastolic blood pressure (DBP), 100-115 mm Hg]." | 5.06 | Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. ( Hörrmann, M; Machwirth, M; Stienen, U; Uberbacher, HJ; van der Does, R; Widmann, L, 1990) |
| "A multicenter, randomized, double-blind, parallel-group trial of 8 weeks' duration was designed to compare the efficacy and safety of once-daily carvedilol with that of twice-daily labetalol in patients with essential hypertension." | 5.06 | Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. ( Bussiere, JL; Durier, P; Gayet, JL; Ollivier, JP, 1990) |
| "Carvedilol and nitrendipine were given for 12 weeks in a double-blind study to 81 elderly patients (greater than or equal to 60 years) with essential hypertension." | 5.06 | Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives. ( Hennig, M; Krönig, B; Machwirth, M; Müller-Beckmann, B; Staiger, C; Stienen, U; Widmann, L, 1990) |
| "A randomized, double-blind, placebo-controlled study was conducted to study the effects of acute and chronic administration of carvedilol in essential hypertension, with special emphasis on renal haemodynamics and function." | 5.06 | Effects of carvedilol on renal function. ( Dupont, AG, 1990) |
| "In an open clinical study, long-term efficacy and safety of carvedilol were investigated in 154 patients with essential hypertension WHO I-II and diastolic blood pressure (BP) between 95 and 115 mm Hg over a period of 1 year." | 5.06 | Efficacy and safety of carvedilol in the treatment of hypertension. ( Glocke, M; Schnurr, E; Widmann, L, 1987) |
| "The effect of once daily low-dose carvedilol on circadian variations of blood pressure (BP) was studied in Japanese patients with mild or moderate essential hypertension." | 5.06 | The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. ( Goto, Y; Iimura, O; Ikeda, M; Ishii, M; Kokubu, T; Kumahara, Y; Murakami, E; Ogihara, T; Takeda, T; Yoshinaga, K, 1987) |
| "Carvedilol and metoprolol were given for 4 weeks in a double-blind study to patients with essential hypertension." | 5.06 | Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. ( Butcher, L; Morgan, T; Snowden, R, 1987) |
| "A randomized, double-blind, placebo-controlled study was set up to study the effects of acute and chronic administration of carvedilol, a vasodilatory beta-blocker in essential hypertension." | 5.06 | Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. ( Block, P; Bossuyt, AM; Dupont, AG; Ingels, M; Jonckheer, MH; Piepsz, A; Six, RO; Taeymans, Y; Van der Niepen, P; Vanhaelst, L, 1987) |
| "Fifty milligrams of carvedilol and 100 mg atenolol were administered in a random order once a day for 2 months to 43 patients with mild to moderate hypertension, in a double-blind crossover study." | 5.06 | Carvedilol and atenolol once daily in the treatment of hypertension. ( Härkönen, R; Hilden, M; Icen, R; Kohvakka, A; Linna, M; Lukkala, K; Luurila, OJ; Sillanpää, J; Vänskä, O, 1989) |
| "The aim of this multicentre, double-blind, randomised, controlled study was to evaluate the antihypertensive effect and to determine the response rates, safety and tolerability of 3 doses of carvedilol (25, 50 and 100 mg) compared with those of pindolol 15 mg, in ambulatory patients with mild to moderate uncomplicated essential hypertension." | 5.06 | Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol. ( Rittinghausen, R, 1988) |
| " The present double-blind placebo-controlled randomized long-term study reports the therapeutic results of the oral administration of a new beta-adrenergic blocking agent, carvedilol, with direct vasodilator activity in patients with primary hypertension." | 5.06 | Follow-up of a method of twenty-four-hour indirect blood pressure monitoring: evaluation of carvedilol, a new antihypertensive agent. ( Distler, A; Gotzen, R; Meyer-Sabellek, W; Schulte, KL, 1987) |
| "A MEDLINE literature search (1966-May 2013) was performed using the following key terms: hypertension, β-blockers, atenolol, carvedilol, metoprolol tartrate, metoprolol succinate, nebivolol, pharmacology, pharmacodynamics, pharmacokinetics, blood pressure, metabolic, lipid, central aortic pressure, diabetes, and insulin resistance." | 4.90 | β-blockers: a review of their pharmacological and physiological diversity in hypertension. ( Ripley, TL; Saseen, JJ, 2014) |
| "Carvedilol is an adrenergic antagonist with nonselective beta- and a1-receptor blocking properties that has demonstrated significant clinical benefit in the management of patients with heart failure and in the post-myocardial infarction setting." | 4.82 | Carvedilol: beta-blockade and beyond. ( Gheorghiade, M; Stroe, AF, 2004) |
| "Carvedilol is a third-generation vasodilating beta-blocker initially approved for the treatment of hypertension." | 4.80 | Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. ( Feuerstein, GZ; Ohlstein, EH; Ruffolo, RR, 1998) |
| "Carvedilol is a vasodilating, beta-adrenoceptor antagonist currently marketed for the treatment of mild to moderate hypertension." | 4.79 | Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. ( Feuerstein, GZ; Ruffolo, RR, 1995) |
| "Carvedilol is a novel, multiple-action cardiovascular drug that is currently approved in many countries for the treatment of hypertension." | 4.79 | Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1997) |
| " Carvedilol, which is a nonselective beta-blocking and alpha 1-blocking drug, with additional Ca(2+)-antagonistic properties, is being developed as an antihypertensive, antianginal drug and as an adjunct therapy in congestive heart failure." | 4.78 | Development of a multiaction beta blocker. Scientific challenges and regulatory needs. ( Lessem, JN; Lukas, MA, 1993) |
| "Carvedilol is a novel multiple-action cardiovascular drug that has recently been introduced to the market for the treatment of mild to moderate hypertension." | 4.78 | Preclinical and clinical pharmacology of carvedilol. ( Boyle, DA; Lukas, MA; Ruffolo, RR; Venuti, RP, 1993) |
| "Several so-called multiple-action compounds have been developed, such as medroxalol (alpha and beta blockade, and beta-2 stimulation), celiprolol (alpha-2 and beta-1 blockade, and beta-2 stimulation) and carvedilol (beta blockade and vasodilatation) for the treatment of patients with arterial hypertension and with coronary heart disease." | 4.78 | Hemodynamic profile of carvedilol. ( Eggeling, T; Haerer, W; Höher, M; Hombach, V; Kochs, M; Schmidt, A; Wieshammer, S, 1990) |
| "Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction." | 3.91 | Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019) |
| "Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation." | 3.83 | Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. ( Akçay, M; Aslan, AN; Baştuğ, S; Bozkurt, E; Durmaz, T; Sari, C; Sari, SÖ, 2016) |
| "This study provides the first evidence to support that ADRB1 polymorphisms play an important role in the DBPs response to carvedilol treatment in patients with essential hypertension." | 3.80 | Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. ( Chen, X; Si, D; Wang, J; Xu, Y; Zhang, M; Zhou, H, 2014) |
| "A case of probable carvedilol-induced thrombocytopenia is reported." | 3.79 | Probable carvedilol-induced thrombocytopenia. ( Aggarwal, A; Alex, S; Cho, A; Chretien, KC, 2013) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 3.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "This prospective post-marketing drug use survey was conducted to assess the safety and efficacy of the β-adrenergic receptor antagonist (β-blocker) Artist® Tablets (carvedilol) in patients with hypertension in Japan." | 3.77 | Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. ( Hiramatsu, K; Iizuka, T; Komiya, M; Matsumoto, T; Mori, Y; Nishikawa, Y; Zenimura, N, 2011) |
| " As an example, this article presents the aggregated dose-response relationship and a subgroup analysis (by age) over all studies of the antihypertensive drug carvedilol." | 3.77 | The once-daily dose regimen of carvedilol: a meta-analysis approach. ( Stienen, U, 1992) |
| "In 102 patients with high risk (52 patients with history of myocardial infarction, 50 patients with history of cerebral stroke within previous 6-48 months) arterial hypertension (AH) we studied clinical efficacy on angiotensin converting enzyme inhibitor (ACEI) lisinopril, calcium antagonist felodipine, and nonselective - -blocker carvedilol in dependence on salt sensitivity of AH." | 3.76 | [Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt]. ( Babkin, AP; Gladkikh, VV; Gulaia, GI; Pershukov, IV, 2010) |
| "Carvedilol is a new substance displaying beta-sympatholytic and vasodilating activities in the same dose range." | 3.76 | A new molecule with vasodilating and beta-adrenoceptor blocking properties. ( Abshagen, U, 1987) |
| " Furthermore, the application of patches containing SS extract-CTN mixture resulted in sustained release of carvedilol, which was able to control the hypertension in deoxycorticosterone acetate (DOCA) induced hypertensive rats through 24 hours." | 3.75 | Transdermal delivery of carvedilol in rats: probing the percutaneous permeation enhancement mechanism of soybean extract-chitosan mixture. ( Jain, S; Sapra, B; Tiwary, AK, 2009) |
| "Aim of the study was to elucidate peculiarities of influence of carvedilol on 24-hour blood pressure (BP) profiles and changes of parameters of cerebral perfusion in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus." | 3.74 | [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus]. ( Belokopytova, NV; Efimova, IIu; Fal'kovskaia, AIu; Mordovin, VF, 2007) |
| "The study showed that L-NAME-induced hypertension has differential effects on endothelial connexins, which respond variously to carvedilol and atenolol." | 3.73 | Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. ( Ko, YS; Lee, PY; Su, CH; Tian, TY; Tsai, CH; Yeh, HI, 2006) |
| "The aims of this study were to examine whether combined blockade of alpha(1) and beta-adrenoceptors with carvedilol postweaning affected the development of hypertension and renal vascular narrowing in spontaneously hypertensive rats (SHR), and whether these effects on pressure and renal vascular changes persisted after treatment withdrawal." | 3.72 | Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing. ( Anderson, WP; Boesen, EI; Denton, KM; Kett, MM, 2004) |
| " The normalization was predicted by the nonischemic etiology of CHF, arterial hypertension, absence of diabetes mellitus, carvedilol therapy, and the dose of carvedilol." | 3.72 | Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. ( Cioffi, G; Opasich, C; Stefenelli, C; Tarantini, L, 2004) |
| "Carvedilol (Coreg/Kredex) is an unselective vasodilating beta-blocker with potent antioxidant activity used in the treatment of hypertension, angina, and congestive heart failure." | 3.70 | Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. ( Barone, FC; Campbell, WG; Feuerstein, GZ; Nelson, AH, 1998) |
| "Carvedilol, a chiral compound possessing nonselective beta- and alpha1-blocking activity, is used for the treatment of hypertension and congestive heart failure (CHF)." | 3.70 | The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ( Boyle, DA; Gehr, TW; Qian, Y; Shusterman, NH; Sica, DA; Tenero, DM, 1999) |
| "The effects of carvedilol, a nonselective beta-blocker with peripheral vasodilator action, on left ventricular function and mass in essential hypertension were studied in 14 patients with diastolic filling abnormalities." | 3.68 | Effect of carvedilol on left ventricular function and mass in hypertension. ( Richardson, PJ; Why, HJ, 1992) |
| "Possible counterregulatory neurohumoral and hemodynamic responses to carvedilol (a new vasodilating nonselective beta-receptor blocker) were studied in 19 men with essential hypertension (age range, 34-59 years; mean age, 44 years)." | 3.68 | Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise. ( Lund-Johansen, P; Myking, O; Omvik, P, 1992) |
| "We assessed the long-term effects of carvedilol on renal function in 10 patients with mild-to-moderate essential hypertension." | 3.68 | Effect of long-term carvedilol therapy on renal function in essential hypertension. ( Marumo, F; Tomita, K, 1992) |
| "The purpose of this study was to investigate the effect of carvedilol on serum lipids in patients with mild-to-moderate essential hypertension." | 3.68 | Effects of carvedilol on serum lipids in patients with essential hypertension. ( Fusegawa, Y; Goto, Y; Homma, Y; Iori, S; Mikami, M; Nakaya, N; Tamachi, H; Yamazaki, A, 1991) |
| "The efficacy, safety, and pharmacokinetics of carvedilol were investigated in an open trial performed on six patients with hypertension and chronic renal failure requiring hemodialysis." | 3.68 | Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. ( Kaifu, Y; Masumura, H; Miki, S; Yuasa, S, 1991) |
| "The effects of a beta-blocker, carvedilol, on peripheral hemodynamics and hemorheologic parameters were evaluated in 11 geriatric patients with essential hypertension [3 men and 8 women aged 62-79 years (mean, 68." | 3.68 | Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension. ( Akedo, Y; Kaku, S; Nagakawa, Y; Orimo, H, 1990) |
| "We studied the effects of oral carvedilol (20 mg/day) on cerebral blood flow (CBF) and CBF autoregulation in ten previous stroke patients with hypertension." | 3.68 | Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. ( Kuriyama, Y; Kyougoku, I; Nakamura, M; Sawada, T, 1990) |
| "By subcutaneous insertion of osmotic minipumps leading to continuous infusion of l-adrenaline, we were able to induce hypertension in normotensive Wistar-Kyoto strain (WKY) rats which was shown to be completely reversible by application of the non-selective beta-adrenoceptor antagonist carvedilol." | 3.68 | Adrenaline in cardiovascular diseases--effect of beta-adrenoceptor antagonists. ( Dehner, R; Grobecker, H; Ikeda, K; Yamori, Y, 1990) |
| "Carvedilol, a combined beta- and alpha 1-blocking drug, was given to 8 young (age 39-47) and 21 old (age 64-79) patients with essential hypertension." | 3.68 | Pharmacokinetics of carvedilol in older and younger patients. ( Adam, W; Anderson, A; Cripps, J; Morgan, T, 1990) |
| "7 years), with previously untreated essential hypertension and echocardiographically proven left-ventricular hypertrophy, received metoprolol 200 mg daily over a period of 12." | 3.67 | [Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block]. ( Behr, M; Franz, IW; Ketelhut, R; Wiewel, D, 1986) |
| "This study was performed to find the optimal dose of carvedilol, in terms of efficacy and safety, in Japanese patients with mild to moderate essential hypertension." | 3.67 | Dose-effect relationship of carvedilol in essential hypertension. An open study. ( Arakawa, K; Goto, Y; Iimura, O; Ishii, M; Kokubu, T; Kumahara, Y; Murakami, E; Ogihara, T; Takeda, T; Yoshinaga, K, 1988) |
| " The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents." | 3.01 | Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial. ( Ashraf, H; Bahreini, M; Ghoghaei, M; Najmeddin, F; Rasooli, F; Salehi, M; Soleimani, A; Solhjoo, M, 2021) |
| "Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure." | 2.77 | A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. ( Carbotta, S; Cittadini, A; Di Michele, S; Galzerano, D; Gaudio, C; Lama, D; Paolisso, G; Tedesco, MA; Tuccillo, B, 2012) |
| "With carvedilol treatment, LVMI was lower (p<0." | 2.75 | Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. ( Mei, Z; Xiaozhen, H; Yu, S; Yun, Z, 2010) |
| " It compares the bioavailability of these two study drugs from a TDDS with conventional immediate release oral tablets in healthy volunteers." | 2.75 | Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ( Aggarwal, A; Agrawal, SS, 2010) |
| "In this study, 1235 participants with type 2 diabetes and hypertension who were receiving renin-angiotensin system blockers were randomized either to carvedilol, receiving 6." | 2.74 | Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. ( Bakris, GL; Bell, DS; McGill, JB, 2009) |
| "In an open prospective 16-week study we carried out assessment of clinical efficacy, vaso- and cardioprotective properties of nonselective alpha and beta-adrenoblocker carvedilol used as monotherapy and in combination with nifedipine or as combination of these drugs with metformin and simvastatin." | 2.74 | [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. ( Eliseeva, IV; Gusakovskaia, LI; Matrosova, IB; Oleĭnikov, VE; Tomashevskaia, IuA, 2009) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 2.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period." | 2.72 | Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. ( Bakris, GL; Fleck, R; Iyengar, M; Sica, DA; Tarka, EA; Weber, MA, 2006) |
| "Nifedipine was effective in 4 of 18 patients, carvedilol, in 4 of 12 patients (22." | 2.71 | Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. ( Angeli, P; Boccagni, P; Burra, P; Carraro, A; Cillo, U; Fagiuoli, S; Fasolato, S; Galioto, A; Gatta, A; Guarda, S; Sartori, M; Semplicini, A; Sticca, A; Zanus, G, 2005) |
| "Carvedilol is an antihypertensive agent which displays unselective beta-blocking, alpha 1-blocking and antioxidant properties." | 2.68 | Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. ( Deetjen, A; Heidland, A; Meyer-Sabellek, W; Pangerl, A; Schaefer, RM, 1995) |
| "Carvedilol treatment also reduced the extent of in vivo LDL oxidation, as reflected by the decrease in antioxidized LDL autoantibody titer." | 2.68 | Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. ( Bellomo, G; Covini, D; Maggi, E; Marchesi, E; Negro, C; Perani, G, 1996) |
| "Carvedilol is a safe, efficient, once/day choice as monotherapy for mild to moderate essential hypertensive patients." | 2.67 | [Use of carvedilol compared to nifedipine in the treatment of mild and moderate essential arterial hypertension]. ( Dantas, M; Freitas, AF; Furtado, MR; Kohlmann, NE; Kohlmann, O; Plavnik, FL; Portela, JE; Spritzer, N; Spritzer, T, 1994) |
| " Since ambulatory blood pressure monitoring in a cross-over trial design can reliably detect differences of 5 mmHg with less than 20 subjects, we have used this technique to assess the dose-response curve of a new beta-blocker, carvedilol." | 2.67 | Antihypertensive effect of carvedilol: a preliminary dose-response study. ( Bird, R; Casadei, B; Coats, AJ; Conway, J, 1992) |
| "Carvedilol is a novel non-selective beta-blocker without intrinsic sympathomimetic activity possessing vasodilatory properties primarily due to an alpha 1-antagonism in the same dose range." | 2.67 | Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure. ( Agrawal, B; Franz, IW; Ketelhut, R; Wiewel, D, 1992) |
| " These results indicate that carvedilol is an effective and safe agent for hypertensive patients with chronic renal failure and for hemodialysis patients with hypertension and that dosage adjustments are probably not required in these clinical situations." | 2.67 | Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. ( Abe, Y; Kaifu, Y; Kitajima, W; Masumura, H; Miki, S, 1992) |
| " Dosing with 25 mg carvedilol once daily or 20 mg nifedipine SR twice daily resulted in mean peak reductions in supine blood pressure of 21/11 and 20/16 mm Hg, respectively, after 1 week of treatment with each respective monotherapy." | 2.67 | Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension. ( de Vries Robles, P; Juttmann, JR; Venuti, RP, 1992) |
| "The efficacy and safety of carvedilol, a beta-blocker with vasodilating properties, were compared at a dosage of 25 to 50 mg once daily with those of atenolol at a dosage of 50-100 mg once daily in a double-blind, randomized, parallel-group, multicenter study." | 2.67 | A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group. ( Young, PH, 1992) |
| "The pharmacokinetic and acute systemic haemodynamic effects of a single oral dose of 50 mg carvedilol has been studied in 24 hypertensive patients with chronic renal failure." | 2.67 | Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. ( Erley, CM; Krämer, BK; Ress, KM; Risler, T, 1992) |
| "Carvedilol was generally well tolerated." | 2.67 | Clinical efficacy of carvedilol in severe hypertension. ( Arakawa, K; Goto, Y; Iimura, I; Ikeda, M; Ishii, M; Kamahara, Y; Kokubu, T; Ogihara, T; Takeda, T; Yoshinaga, K, 1991) |
| " Nine patients experienced adverse events during combination treatment." | 2.67 | The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics. ( Dupont, AG; Schoors, DF; Venuti, RP, 1990) |
| "Carvedilol (BM 14190) is a new potent and well-tolerated beta-adrenoceptor antagonist with vasodilating properties." | 2.66 | Circadian antihypertensive profile of carvedilol (BM 14190). ( Distler, A; Gotzen, R; Meyer-Sabellek, W; Schulte, KL, 1987) |
| "Carvedilol (BM14190) is a new compound with combined properties of nonselective beta-adrenoceptor blockade, devoid of ISA, and precapillary vasodilatation." | 2.66 | Hemodynamic effects of combined beta-adrenoceptor blockade and precapillary vasodilatation in hypertension. ( Andrén, L; Eggertsen, R; Hansson, L; Sivertsson, R, 1985) |
| " The patients received either carvedilol 25mg twice daily or metoprolol 50mg twice daily for a period of 4 weeks; if diastolic blood pressure was over 90mm Hg at this time, the dosage was doubled for the subsequent 4 weeks." | 2.66 | Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. ( Ehmer, B; Rudorf, J; van der Does, R, 1988) |
| "Carvedilol was well tolerated; 2 patients experienced dizziness associated with postural hypotension after administration of the 50mg dose." | 2.66 | Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ( McPhillips, JJ; Patterson, D; Schwemer, GT; Scott, DI; Zinny, M, 1988) |
| "Carvedilol (BM 14190) is a new compound with combined nonselective beta-adrenoceptor blocking activity, devoid of ISA, and a precapillary vasodilating effect." | 2.65 | Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. ( Andrén, L; Eggertsen, R; Hansson, L; Sivertsson, R, 1984) |
| "Carvedilol was evaluated acutely with invasive (dye-dilution) and noninvasive (plethysmography) technique and showed an acute antihypertensive effect without causing a rise in TPR and with a decrease in regional resistance in the fore-arm." | 2.65 | Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress. ( Eggertsen, R, 1984) |
| "Carvedilol (BM 14190) is a new antihypertensive compound which combines beta-adrenoceptor blocking and precapillary vasodilating properties but is devoid of intrinsic sympathomimetic activity." | 2.65 | Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. ( Andrén, L; Eggertsen, R; Hansson, L; Sivertsson, R, 1984) |
| "Intradialytic hypertension is a condition where there is an increase in blood pressure (BP) from pre- to post-hemodialysis; this condition has been recently identified as an independent mortality risk factor in hypertensive hemodialysis patients." | 2.53 | Mechanisms and Treatment of Intradialytic Hypertension. ( Inrig, JK; Van Buren, PN, 2016) |
| "Hypertension is common in hemodialysis patients and contributes to this population's high risk for cardiovascular morbidity and mortality." | 2.48 | Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. ( Inrig, JK; Toto, R; Van Buren, PN, 2012) |
| "The utility of β-blockers in the treatment of hypertension has created much speculation as to their efficacy in patients with comorbid conditions, and there are concerns regarding their adverse metabolic effects." | 2.48 | Vasodilating versus first-generation β-blockers for cardiovascular protection. ( Fares, H; Lavie, CJ; Ventura, HO, 2012) |
| "Carvedilol is a vasodilating noncardioselective third-generation β-blocker, without the negative hemodynamic and metabolic effects of traditional β-blockers, which can be used as a cardioprotective agent." | 2.48 | Use of carvedilol in hypertension: an update. ( Egan, CG; Leonetti, G, 2012) |
| "Carvedilol is a beta(1)- and beta(2)-adrenergic receptor antagonist with additional vasodilatory alpha(1)-blocking properties." | 2.45 | Role of carvedilol controlled-release in cardiovascular disease. ( Fonarow, GC, 2009) |
| "Beta-blockers have been used to treat hypertension for decades, either as monotherapy or combined with other antihypertensive agents, primarily diuretics, often as fixed-dose combination products." | 2.44 | Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy. ( Black, HR; Sica, DA, 2008) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential." | 2.41 | Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. ( Cheng, J; Kamiya, K; Kodama, I, 2001) |
| "Carvedilol is a new beta-blocker antihypertensive agent with vasodilating properties secondary to alpha 1-blocking activity." | 2.40 | Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. ( Frishman, W; Moser, M, 1998) |
| "Today congestive heart failure due to underlying coronary heart disease is by far more common than the hypertension-induced variety." | 2.40 | Hypertension-induced congestive heart failure. ( Hansson, L, 1998) |
| "Carvedilol is a novel antihypertensive agent." | 2.40 | Carvedilol in the treatment of hypertension--a review of the clinical data base. ( Hansson, L; Himmelmann, A, 1998) |
| "Patients with hypertension are at increased risk of developing heart failure (HF), but the mechanisms by which hypertension leads to HF have not been clarified [although left ventricular hypertrophy (LVH) is clearly a predictor of an increased risk of HF]." | 2.40 | Progression from hypertension to heart failure. Mechanisms and management. ( Cleland, JG, 1999) |
| "Carvedilol is an arylethanolamine that is a racemic mixture of 2 enantiomers." | 2.39 | Clinical pharmacokinetics and pharmacodynamics of carvedilol. ( Morgan, T, 1994) |
| "Carvedilol is a beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade." | 2.38 | Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. ( Campoli-Richards, D; McTavish, D; Sorkin, EM, 1993) |
| "However, the treatment of hypertension in older patients is often complicated by the presence of concomitant disorders." | 2.38 | Antihypertensive treatment with a dual-acting beta-blocker in the elderly. ( Lessem, JN; Weber, MA, 1993) |
| "Carvedilol is a nonselective beta-adrenoceptor antagonist, devoid of intrinsic sympathomimetic activity and possessing selective alpha 1-adrenoceptor-blocking activity, although this is considerably weaker than its beta-adrenoceptor antagonistic activity." | 2.38 | Pharmacodynamic profile of carvedilol. ( van Zwieten, PA, 1993) |
| "The drug has a place in the chronic treatment of hypertension and in the therapy of hypertensive emergencies." | 2.38 | Clinical experience with dual-acting drugs in hypertension. ( Rahn, KH, 1992) |
| " As an example, this paper presents the aggregated dose-response relationship of efficacy data and a last-value analysis of laboratory data across all studies of the antihypertensive drug project carvedilol." | 2.38 | Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach. ( Meyer-Sabellek, W; Stienen, U, 1992) |
| "Carvedilol is a dual-acting drug designed to produce two complementary effects: beta-blockade and vasodilation." | 2.38 | Vasodilatory action of carvedilol. ( Bartsch, W; Müller-Beckmann, B; Sponer, G; Strein, K, 1992) |
| "Carvedilol is a third-generation vasodilating beta-adrenoceptor antagonist with advantageous ancillary pharmacologic properties for the treatment of the patient with high blood pressure complicated by CAD." | 2.38 | Hypertension and coronary artery disease: a therapeutic challenge. ( Taylor, SH, 1991) |
| "Carvedilol is a new compound that combines beta-receptor blockade and vasodilation in one molecule." | 2.37 | Antihypertensive compounds with combined actions. ( Rahn, KH, 1987) |
| "Carvedilol was well tolerated." | 1.62 | Better peridialytic blood pressure control using carvedilol in end stage renal disease patients on twice weekly maintenance hemodialysis. ( Chandra, A; Mishra, P; Rao, N; Srivastava, D, 2021) |
| "Hypertension is one of the dangerous health conditions prevalent in society, is a risk factor for several other diseases if left untreated and anti-hypertensives (AHs) are the approved drugs to treat it." | 1.56 | Network-based approach highlighting interplay among anti-hypertensives: target coding-genes: diseases. ( Sharma, R, 2020) |
| "Hallucinations are rarely reported and as far as we know the only reported couple of cases were on metoprolol and propranolol, none has been reported with Carvedilol." | 1.51 | The Man Who Saw Things on Carvedilol. ( Aikoye, SA; Jafferany, M; Osuagwu, V; Plath, DL, 2019) |
| "Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta." | 1.46 | Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. ( Berg, G; Bertera, FM; Carranza, A; Chiappetta, DA; Del Mauro, JS; Donato, M; Fernandez Machulsky, N; Gelpi, RJ; González, GE; Gorzalczany, SB; Höcht, C; Morales, C; Morettón, MA; Prince, PD; Taira, CA, 2017) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| "Echocardiography showed 73% dilated cardiomyopathy; 83% showed moderate to severe LV systolic dysfunction (mean EF 36." | 1.43 | Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti. ( Malebranche, R; Morisset, PH; Raphael, NA; Tabou Moyo, C; Wilentz, JR, 2016) |
| "To report a case of difficult-to-treat hypertension ultimately managed with triple antirenin (anti-R) therapy using plasma renin activity (PRA) to guide medication selection." | 1.40 | Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension. ( Coakley, C; Hough, A; Parra, D; Shah, S, 2014) |
| "To report a case of difficult-to-treat hypertension ultimately managed with triple antirenin (anti-R) therapy using plasma renin activity (PRA) to guide medication selection." | 1.39 | Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension. ( Coakley, C; Hough, A; Parra, D; Shah, S, 2013) |
| " Carvedilol showed enantioselective pharmacokinetic properties with increased distribution in F rats compared with normotensive animals." | 1.38 | Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats. ( Bertera, F; Buontempo, F; Chiappetta, D; Di Verniero, CA; Höcht, C; Mayer, MA; Polizio, AH; Taira, CA, 2012) |
| " Although pharmacokinetic properties of carvedilol remained mainly unaffected in SH rats with regard to WKY rats, hypertensive animals showed a reduction in drug clearance of R- and S-carvedilol after administration of 1 mg kg(-1) compared with WKY rats." | 1.38 | Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. ( Bertera, FM; Buontempo, F; Chiappetta, D; Del Mauro, JS; Höcht, C; Polizio, AH; Taira, CA, 2012) |
| "Carvedilol is an antihypertensive drug available as a racemic mixture." | 1.38 | Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry. ( Bertucci, C; Coelho, EB; Da Silva, FG; Lanchote, VL; Marques, MP; Poggi, JC, 2012) |
| "Carvedilol showed enantioselective non-linear pharmacokinetic properties in both groups." | 1.36 | Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. ( Bernabeu, E; Bertera, F; Bramuglia, GF; Buontempo, F; Chiappetta, D; Di Verniero, CA; Höcht, C; Mayer, MA; Taira, CA, 2010) |
| " The number and type of antihypertensive drugs have increased dramatically from 28 diuretics in 1972 to over 125 agents today, including fixed dose combination dosage forms." | 1.36 | The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. ( Black, HR; Greenberg, BH; Weber, MA, 2010) |
| "Co-treatment with losartan and carvedilol reduced the renal vasoconstrictor responses to exogenously administered vasoactive agents but to a lesser extent than losartan or carvedilol alone." | 1.35 | Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats. ( Abdulla, MH; Abdullah, NA; Johns, EJ; Khan, MA; Sattar, MA, 2009) |
| "A 2 s pause with presyncope and a hypotension (blood pressure values were 80/70 mm Hg) were observed after 2 min in the provocation phase." | 1.35 | Pharmacological washout for the correct evaluation of the head-up tilt testing. ( Coglitore, S; Di Bella, G; Patanè, S; Pugliatti, P; Recupero, A, 2008) |
| " The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration." | 1.34 | Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. ( Ahmad, FJ; Khar, RK; Reddy, MV; Ruckmani, K; Ubaidulla, U, 2007) |
| " As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed." | 1.34 | [Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension]. ( Frese, T; Sandholzer, H, 2007) |
| "Carvedilol was administered in 379 hypertensive patients with high risk factors such as NIDDM, lipid disorders or abnormal serum creatinine level and 364 primary hypertensive patients without risk factors." | 1.33 | [Efficiency and safety of carvedilol treatment in high risk hypertensive patients]. ( Hu, DY; Zhao, XL, 2006) |
| "Carvedilol treatment significantly blocked adrenoceptors during the treatment period, delayed development (eye opening), reduced growth, and reduced arterial pressure and heart rate." | 1.32 | Pre-weaning carvedilol treatment in spontaneously hypertensive rats. ( Anderson, WP; Boesen, EI; Kett, MM; Lambert, GW, 2004) |
| "2." | 1.31 | Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. ( Barone, F; Brooks, DP; Campbell, WG; Contino, LC; Gygielko, E; Laping, NJ; Nelson, AH; Olson, BA; Wong, VY, 2001) |
| "Carvedilol is a novel non-selective beta-blocker without intrinsic sympathomimetic activity (ISA) and has vasodilating effect through blocking alpha 1 receptor." | 1.31 | [Effects of carvedilol on the hemodynamics and its tolerance in elderly patients]. ( Asai, T; Iguchi, A; Kanda, S; Koike, A; Kuzuya, M; Maeda, K, 2002) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "Carvedilol is a beta blocker with alpha-blocking activity and its profile of action is similar to that of a combination of a beta blocker and a diuretic." | 1.29 | Carvedilol in hypertension. ( Raftery, EB, 1993) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 1.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Carvedilol is a new beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade." | 1.29 | [Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension]. ( Barra, M; Gigli, G; Orlandi, S; Perocchio, M; Rosolen, GA; Sacchetti, R; Vallebona, A, 1996) |
| "Carvedilol is an effective antihypertensive agent, and the hemodynamic mode of action reflects alpha 1- and beta 1-blocking activities." | 1.28 | Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. ( Lund-Johansen, P; Nordrehaug, JE; Omvik, P; White, W, 1992) |
| "Carvedilol is a recently developed antihypertensive drug that combines in the same molecule a nonselective beta-adrenoceptor blocking effect and a vasodilating precapillary activity." | 1.27 | Resting and postexercise hemodynamic effects of carvedilol, a beta-adrenergic blocker and precapillary vasodilator in hypertensive patients. ( Boselli, L; Cuspidi, C; Leonetti, G; Rupoli, L; Sampieri, L; Terzoli, L; Zanchetti, A, 1987) |
| " Labetalol and prazosin also significantly shifted the dose-response curve to the right for phenylephrine but not for angiotensin II." | 1.27 | Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats. ( Akashi, A; Hashimoto, H; Kanda, A; Tanaka, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (8.95) | 18.7374 |
| 1990's | 105 (33.55) | 18.2507 |
| 2000's | 95 (30.35) | 29.6817 |
| 2010's | 72 (23.00) | 24.3611 |
| 2020's | 13 (4.15) | 2.80 |
| Authors | Studies |
|---|---|
| Ghazi, L | 1 |
| Li, F | 1 |
| Chen, X | 2 |
| Simonov, M | 1 |
| Yamamoto, Y | 1 |
| Biswas, A | 1 |
| Hanna, J | 1 |
| Shah, T | 1 |
| Peixoto, AJ | 1 |
| Wilson, FP | 1 |
| Rode, M | 1 |
| Nenoff, K | 1 |
| Wirkner, K | 1 |
| Horn, K | 1 |
| Teren, A | 1 |
| Regenthal, R | 1 |
| Loeffler, M | 1 |
| Thiery, J | 1 |
| Aigner, A | 1 |
| Pott, J | 1 |
| Kirsten, H | 1 |
| Scholz, M | 1 |
| Li, XT | 1 |
| Zhang, W | 1 |
| Deng, G | 1 |
| Hu, J | 2 |
| Yan, R | 1 |
| Fan, J | 1 |
| Moctezuma-Velazquez, C | 1 |
| Abraldes, JG | 1 |
| Yin, T | 1 |
| Alquist, CR | 1 |
| Sharma, R | 1 |
| Chandra, A | 1 |
| Rao, N | 1 |
| Srivastava, D | 1 |
| Mishra, P | 1 |
| Pearson, JT | 1 |
| Thambyah, HP | 1 |
| Waddingham, MT | 1 |
| Inagaki, T | 1 |
| Sukumaran, V | 1 |
| Ngo, JP | 1 |
| Ow, CPC | 1 |
| Sonobe, T | 1 |
| Chen, YC | 1 |
| Edgley, AJ | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Tsuchimochi, H | 1 |
| Shirai, M | 1 |
| Chan You, S | 1 |
| Krumholz, HM | 1 |
| Suchard, MA | 1 |
| Schuemie, MJ | 1 |
| Hripcsak, G | 1 |
| Chen, R | 1 |
| Shea, S | 1 |
| Duke, J | 1 |
| Pratt, N | 1 |
| Reich, CG | 1 |
| Madigan, D | 1 |
| Ryan, PB | 1 |
| Woong Park, R | 1 |
| Park, S | 1 |
| Farshi, A | 1 |
| DalirAkbari, N | 1 |
| Zomorrodi, A | 1 |
| Khalili, M | 1 |
| Mahmoudinezhad, M | 1 |
| Najmeddin, F | 1 |
| Solhjoo, M | 1 |
| Ashraf, H | 1 |
| Salehi, M | 1 |
| Rasooli, F | 1 |
| Ghoghaei, M | 1 |
| Soleimani, A | 1 |
| Bahreini, M | 1 |
| Del Mauro, JS | 2 |
| Prince, PD | 1 |
| Donato, M | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| González, GE | 1 |
| Bertera, FM | 2 |
| Carranza, A | 1 |
| Gorzalczany, SB | 1 |
| Chiappetta, DA | 1 |
| Berg, G | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Taira, CA | 4 |
| Höcht, C | 4 |
| Domagoj, M | 1 |
| Branka, JZ | 1 |
| Jelena, M | 1 |
| Davor, M | 1 |
| Duska, G | 1 |
| Eibel, B | 1 |
| Kristochek, M | 1 |
| Peres, TR | 1 |
| Dias, LD | 1 |
| Dartora, DR | 1 |
| Casali, KR | 1 |
| Kalil, RAK | 1 |
| Lehnen, AM | 1 |
| Irigoyen, MC | 1 |
| Markoski, MM | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Egan, B | 1 |
| Flack, J | 1 |
| Patel, M | 1 |
| Lombera, S | 1 |
| Laha, B | 1 |
| Goswami, R | 1 |
| Maiti, S | 1 |
| Sen, KK | 1 |
| Kishi, T | 1 |
| Fujii, E | 1 |
| Aikoye, SA | 1 |
| Jafferany, M | 1 |
| Osuagwu, V | 1 |
| Plath, DL | 1 |
| Hanauer Schaab, E | 1 |
| Lanchote, VL | 2 |
| Balthazar Nardotto, GH | 1 |
| Marques Pereira, MP | 1 |
| Dantas, M | 2 |
| Paiva, CE | 1 |
| Barbosa Coelho, E | 1 |
| Alex, S | 1 |
| Chretien, KC | 1 |
| Cho, A | 1 |
| Aggarwal, A | 2 |
| Mamedov, MN | 1 |
| Mustafaev, II | 1 |
| Nurmamedova, GS | 1 |
| Lewandowski, J | 1 |
| Sinski, M | 1 |
| Symonides, B | 1 |
| Korecki, J | 1 |
| Rogowski, K | 1 |
| Judycki, J | 1 |
| Sieczych, A | 1 |
| Możeńska, O | 1 |
| Gaciong, Z | 1 |
| Woo, HH | 1 |
| Kim, EJ | 1 |
| Song, WH | 1 |
| Lee, JU | 1 |
| Shin, MS | 1 |
| Lee, S | 1 |
| Kim, BO | 1 |
| Hong, KS | 1 |
| Han, SW | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Salvi, P | 2 |
| Pucci, G | 1 |
| Battista, F | 1 |
| Schillaci, G | 1 |
| Studinger, P | 1 |
| Tabák, ÁG | 1 |
| Chen, CH | 1 |
| Othmane, TE | 1 |
| Torzsa, P | 1 |
| Kapocsi, J | 1 |
| Fekete, BC | 1 |
| Tislér, A | 1 |
| Shah, S | 2 |
| Coakley, C | 2 |
| Hough, A | 2 |
| Parra, D | 2 |
| Textor, SC | 1 |
| Degirmenci, H | 1 |
| Açikel, M | 1 |
| Bakirci, EM | 1 |
| Duman, H | 1 |
| Demirelli, S | 1 |
| Tas, H | 1 |
| Simsek, Z | 1 |
| Karakelleoglu, S | 1 |
| Aksakal, E | 1 |
| Erol, MK | 1 |
| Ripley, TL | 1 |
| Saseen, JJ | 1 |
| Kuz'min, OB | 1 |
| Belianin, VV | 1 |
| Zhezha, VV | 1 |
| Si, D | 1 |
| Wang, J | 1 |
| Xu, Y | 1 |
| Zhang, M | 1 |
| Zhou, H | 1 |
| Szentes, V | 2 |
| Kovács, G | 1 |
| Dézsi, CA | 2 |
| Cao, G | 1 |
| Llambí, HG | 1 |
| Ottaviano, G | 1 |
| Muller, A | 1 |
| Milei, J | 1 |
| Diogo, LN | 1 |
| Pereira, SA | 1 |
| Nunes, AR | 1 |
| Afonso, RA | 1 |
| Santos, AI | 1 |
| Monteiro, EC | 2 |
| Wong, GW | 1 |
| Laugerotte, A | 1 |
| Wright, JM | 1 |
| Aslan, AN | 1 |
| Sari, C | 1 |
| Baştuğ, S | 1 |
| Sari, SÖ | 1 |
| Akçay, M | 1 |
| Durmaz, T | 1 |
| Bozkurt, E | 1 |
| Van Buren, PN | 2 |
| Inrig, JK | 3 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Mircheva, M | 1 |
| Rathmann, N | 1 |
| Diehl, S | 1 |
| Krämer, BK | 2 |
| Benck, U | 1 |
| Fi, Z | 1 |
| Nádházi, Z | 1 |
| Malebranche, R | 1 |
| Tabou Moyo, C | 1 |
| Morisset, PH | 1 |
| Raphael, NA | 1 |
| Wilentz, JR | 1 |
| Bell, DS | 8 |
| Bakris, GL | 14 |
| McGill, JB | 7 |
| Galioto, A | 2 |
| Semplicini, A | 4 |
| Zanus, G | 2 |
| Fasolato, S | 2 |
| Sticca, A | 2 |
| Boccagni, P | 2 |
| Frigo, AC | 1 |
| Cillo, U | 2 |
| Gatta, A | 2 |
| Angeli, P | 2 |
| Sica, DA | 5 |
| Black, HR | 2 |
| Stafylas, PC | 1 |
| Sarafidis, PA | 2 |
| Weber, MA | 7 |
| Carter, NJ | 1 |
| Keating, GM | 1 |
| Sapra, B | 3 |
| Jain, S | 3 |
| Tiwary, AK | 3 |
| Shal'nova, SA | 1 |
| Martsevich, SIu | 1 |
| Deev, AD | 1 |
| Lukina, IuV | 1 |
| Oganov, RG | 1 |
| Riabykina, GV | 1 |
| Chazova, IE | 1 |
| Mychka, VB | 1 |
| Shutova, LI | 1 |
| Shishova, TV | 1 |
| Liutikova, LN | 1 |
| Kozhemiakina, ESh | 1 |
| Shchedrina, EV | 1 |
| Sobolev, AV | 1 |
| Jovanovic, D | 1 |
| Jovovic, D | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Miloradovic, Z | 1 |
| Naumovic, R | 1 |
| Dimitrijevic, J | 1 |
| Maksic, N | 1 |
| Djukanovic, L | 1 |
| Phillips, RA | 6 |
| Fonseca, V | 7 |
| Katholi, RE | 6 |
| Messerli, FH | 8 |
| Raskin, P | 6 |
| Wright, JT | 6 |
| Iyengar, M | 6 |
| Anderson, KM | 6 |
| Lukas, MA | 10 |
| Abdulla, MH | 1 |
| Sattar, MA | 1 |
| Khan, MA | 1 |
| Abdullah, NA | 1 |
| Johns, EJ | 1 |
| Wegscheider, K | 1 |
| Frishman, WH | 2 |
| Henderson, LS | 2 |
| Pedersen, ME | 1 |
| Cockcroft, JR | 1 |
| Fonarow, GC | 1 |
| Bakris, G | 1 |
| Manrique, C | 1 |
| Giles, TD | 2 |
| Ferdinand, KC | 1 |
| Sowers, JR | 1 |
| Bakovic, D | 1 |
| Pivac, N | 1 |
| Eterovic, D | 1 |
| Palada, I | 1 |
| Valic, Z | 1 |
| Paukovic-Sekulic, B | 1 |
| Dujic, Z | 1 |
| Che, Q | 1 |
| Schreiber, MJ | 1 |
| Rafey, MA | 1 |
| Xiaozhen, H | 1 |
| Yun, Z | 1 |
| Mei, Z | 1 |
| Yu, S | 1 |
| Oleĭnikov, VE | 1 |
| Matrosova, IB | 1 |
| Eliseeva, IV | 1 |
| Tomashevskaia, IuA | 1 |
| Gusakovskaia, LI | 1 |
| Iarkova, NA | 1 |
| Borovkov, NN | 1 |
| Agrawal, SS | 1 |
| Carella, AM | 1 |
| Antonucci, G | 1 |
| Conte, M | 1 |
| Di Pumpo, M | 1 |
| Giancola, A | 1 |
| Antonucci, E | 1 |
| Polónia, J | 1 |
| Barbosa, L | 1 |
| Silva, JA | 1 |
| Bertoquini, S | 1 |
| Di Verniero, CA | 2 |
| Bertera, F | 2 |
| Buontempo, F | 3 |
| Bernabeu, E | 1 |
| Chiappetta, D | 3 |
| Mayer, MA | 2 |
| Bramuglia, GF | 1 |
| Chen, WQ | 1 |
| Cai, H | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Zhang, Y | 1 |
| O-Uchi, J | 1 |
| Lopes, CM | 1 |
| Ordronneau, P | 1 |
| Flack, JM | 1 |
| Greenberg, BH | 1 |
| Latfullin, IA | 1 |
| Ishmurzin, GP | 1 |
| Gaĭfullina, RF | 1 |
| Akhmerova, RI | 1 |
| Kim, ZF | 1 |
| Podol'skaia, AA | 1 |
| Babkin, AP | 1 |
| Gladkikh, VV | 1 |
| Pershukov, IV | 1 |
| Gulaia, GI | 1 |
| De Caterina, AR | 1 |
| Leone, AM | 1 |
| Sharma, PP | 1 |
| Shah, M | 1 |
| Deedwania, P | 1 |
| Erdoğan, O | 1 |
| Ertem, B | 1 |
| Altun, A | 1 |
| Sehrt, D | 1 |
| Meineke, I | 1 |
| Tzvetkov, M | 1 |
| Gültepe, S | 1 |
| Brockmöller, J | 1 |
| Mori, Y | 1 |
| Nishikawa, Y | 1 |
| Iizuka, T | 1 |
| Zenimura, N | 1 |
| Matsumoto, T | 1 |
| Hiramatsu, K | 1 |
| Komiya, M | 1 |
| Conde, SV | 1 |
| Nunes da Silva, T | 1 |
| Gonzalez, C | 1 |
| Mota Carmo, M | 1 |
| Guarino, MP | 1 |
| Marazzi, G | 1 |
| Volterrani, M | 1 |
| Caminiti, G | 1 |
| Iaia, L | 1 |
| Massaro, R | 1 |
| Vitale, C | 1 |
| Sposato, B | 1 |
| Mercuro, G | 1 |
| Rosano, G | 1 |
| Polizio, AH | 2 |
| Wehland, M | 1 |
| Grosse, J | 1 |
| Simonsen, U | 1 |
| Infanger, M | 1 |
| Bauer, J | 1 |
| Grimm, D | 1 |
| Toto, R | 2 |
| Shah, NK | 1 |
| Smith, SM | 1 |
| Nichols, WW | 1 |
| Lo, MC | 1 |
| Ashfaq, U | 1 |
| Satish, P | 1 |
| Johnson, JA | 1 |
| Epstein, BJ | 1 |
| DiNicolantonio, JJ | 1 |
| Hackam, DG | 1 |
| Poggi, JC | 1 |
| Da Silva, FG | 1 |
| Coelho, EB | 1 |
| Marques, MP | 1 |
| Bertucci, C | 1 |
| Kelly, AS | 2 |
| Gonzalez-Campoy, JM | 2 |
| Rudser, KD | 1 |
| Katz, H | 1 |
| Metzig, AM | 1 |
| Thalin, M | 1 |
| Bank, AJ | 2 |
| Baulmann, J | 1 |
| Schunkert, H | 1 |
| Signorovitch, JE | 1 |
| Samuelson, TM | 1 |
| Ramakrishnan, K | 1 |
| Marynchenko, M | 1 |
| Wu, EQ | 1 |
| Blum, SI | 1 |
| Ramasamy, A | 1 |
| Chen, S | 1 |
| Fares, H | 1 |
| Lavie, CJ | 1 |
| Ventura, HO | 1 |
| Galzerano, D | 2 |
| Di Michele, S | 1 |
| Paolisso, G | 2 |
| Tuccillo, B | 2 |
| Lama, D | 2 |
| Carbotta, S | 1 |
| Cittadini, A | 1 |
| Tedesco, MA | 2 |
| Gaudio, C | 1 |
| Ozbilen, S | 1 |
| Eren, MA | 1 |
| Turan, MN | 1 |
| Sabuncu, T | 1 |
| Leonetti, G | 2 |
| Egan, CG | 1 |
| Van Buren, P | 1 |
| Kim, C | 1 |
| Vongpatanasin, W | 1 |
| Povsic, TJ | 1 |
| Zepeda, RJ | 1 |
| Castillo, R | 1 |
| Rodrigo, R | 1 |
| Prieto, JC | 1 |
| Aramburu, I | 1 |
| Brugere, S | 1 |
| Galdames, K | 1 |
| Noriega, V | 1 |
| Miranda, HF | 1 |
| Saul, SM | 1 |
| Duprez, DA | 1 |
| Zhong, W | 1 |
| Grandits, GA | 1 |
| Cohn, JN | 1 |
| Sayin, MR | 1 |
| Aydin, M | 1 |
| Dogan, SM | 1 |
| Karabag, T | 1 |
| Cetiner, MA | 1 |
| Aktop, Z | 1 |
| Calò, L | 1 |
| Giacon, B | 1 |
| Davis, PA | 2 |
| Pagnin, E | 1 |
| Piccin, A | 1 |
| Riegler, P | 1 |
| Huber, W | 1 |
| Antonello, A | 1 |
| Anguita Sánchez, M | 2 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Pfeffer, M | 1 |
| Vita, JA | 1 |
| Maeda, K | 3 |
| Yasunari, K | 2 |
| Sato, EF | 1 |
| Yoshikawa, J | 2 |
| Inoue, M | 1 |
| Kett, MM | 2 |
| Denton, KM | 1 |
| Boesen, EI | 2 |
| Anderson, WP | 2 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Okajima, K | 1 |
| Harada, N | 1 |
| Uchiba, M | 1 |
| Isobe, H | 1 |
| Watanabe, K | 1 |
| Abe, Y | 2 |
| Sato, S | 1 |
| Wahed, M | 1 |
| Wen, J | 1 |
| Narasimman, G | 1 |
| Ma, M | 1 |
| Ali, F | 1 |
| Saito, Y | 1 |
| Suresh, P | 1 |
| Shirai, K | 1 |
| Soga, M | 1 |
| Nagai, Y | 1 |
| Takahashi, T | 1 |
| Hasegawa, G | 1 |
| Naito, M | 1 |
| Tachikawa, H | 1 |
| Tanabe, N | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Yamaguchi, K | 1 |
| Miyazaki, M | 1 |
| Kakemi, M | 1 |
| Lambert, GW | 1 |
| Nakamura, M | 2 |
| Watanabe, T | 1 |
| Asada, A | 1 |
| Friesewinkel, O | 1 |
| Furrer, M | 1 |
| Hänggi, G | 1 |
| Rutschmann, A | 1 |
| Yamagata, K | 1 |
| Ichinose, S | 1 |
| Tagami, M | 1 |
| Grossman, E | 1 |
| Stroe, AF | 1 |
| Gheorghiade, M | 1 |
| Cioffi, G | 1 |
| Stefenelli, C | 1 |
| Tarantini, L | 1 |
| Opasich, C | 1 |
| Vyssoulis, GP | 1 |
| Marinakis, AG | 1 |
| Aznaouridis, KA | 1 |
| Karpanou, EA | 1 |
| Arapogianni, AN | 1 |
| Cokkinos, DV | 1 |
| Stefanadis, CI | 1 |
| Oakes, R | 1 |
| Calò, LA | 1 |
| Gonzalez-Feldman, E | 1 |
| Marfella, R | 3 |
| Siniscalchi, M | 1 |
| Nappo, F | 1 |
| Gualdiero, P | 1 |
| Esposito, K | 1 |
| Sasso, FC | 1 |
| Cacciapuoti, F | 1 |
| Di Filippo, C | 1 |
| Rossi, F | 1 |
| D'Amico, M | 1 |
| Giugliano, D | 3 |
| Lee, J | 1 |
| Lee, M | 1 |
| Kim, JU | 1 |
| Song, KI | 1 |
| Choi, YS | 1 |
| Cheong, SS | 1 |
| Guarda, S | 1 |
| Burra, P | 1 |
| Fagiuoli, S | 1 |
| Sartori, M | 1 |
| Carraro, A | 1 |
| Williams, RE | 1 |
| Praskurnichiĭ, EA | 3 |
| Shevchenko, OP | 3 |
| Makarova, SV | 3 |
| Zhukova, VA | 3 |
| Tammaro, P | 1 |
| del Viscovo, L | 1 |
| Galzerano, A | 1 |
| Breglio, R | 1 |
| Capogrosso, P | 1 |
| Bader, FM | 1 |
| Hagan, ME | 1 |
| Crompton, JA | 1 |
| Gilbert, EM | 1 |
| Yeh, HI | 1 |
| Lee, PY | 1 |
| Su, CH | 1 |
| Tian, TY | 1 |
| Ko, YS | 1 |
| Tsai, CH | 1 |
| Zhang, YJ | 1 |
| Xiang, MX | 1 |
| San, J | 1 |
| Cheng, G | 1 |
| Wang, SS | 1 |
| Zhao, XL | 1 |
| Hu, DY | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Yorulmaz, E | 1 |
| Shapiro, R | 1 |
| Thai, NL | 1 |
| Natale, F | 1 |
| Calabrò, R | 1 |
| Mizuta, Y | 1 |
| Imaizumi, T | 1 |
| Fardoun, RZ | 1 |
| Tenero, DM | 2 |
| Baidoo, CA | 1 |
| Campanile, AM | 1 |
| Harter, AH | 1 |
| Boyle, D | 1 |
| Danoff, TM | 1 |
| Tarka, EA | 3 |
| Waterhouse, B | 2 |
| Goulding, MR | 1 |
| Madan, A | 1 |
| St John Sutton, M | 1 |
| Miller, AB | 1 |
| Reichek, N | 1 |
| Fleck, R | 2 |
| Tereshchenko, SN | 1 |
| Dzhaiani, NA | 1 |
| Morozova, MN | 1 |
| Dalal, MR | 1 |
| Ubaidulla, U | 1 |
| Reddy, MV | 1 |
| Ruckmani, K | 1 |
| Ahmad, FJ | 1 |
| Khar, RK | 1 |
| Pugliatti, P | 1 |
| Patanè, S | 1 |
| Recupero, A | 1 |
| Coglitore, S | 1 |
| Di Bella, G | 1 |
| Thelen, AM | 1 |
| Kaiser, DR | 1 |
| Bangalore, S | 1 |
| Holdbrook, FK | 2 |
| Malfatto, G | 1 |
| Branzi, G | 1 |
| Ciambellotti, F | 1 |
| Valli, P | 1 |
| Bizzi, C | 1 |
| Facchini, M | 1 |
| Frese, T | 1 |
| Sandholzer, H | 1 |
| Mordovin, VF | 1 |
| Belokopytova, NV | 1 |
| Fal'kovskaia, AIu | 1 |
| Efimova, IIu | 1 |
| Savel'eva, SA | 2 |
| Eggertsen, R | 6 |
| Andrén, L | 4 |
| Sivertsson, R | 4 |
| Hansson, L | 7 |
| Dominiak, P | 1 |
| Plavnik, FL | 1 |
| Freitas, AF | 1 |
| Portela, JE | 1 |
| Spritzer, T | 1 |
| Kohlmann, NE | 1 |
| Spritzer, N | 1 |
| Furtado, MR | 1 |
| Kohlmann, O | 1 |
| McTavish, D | 1 |
| Campoli-Richards, D | 1 |
| Sorkin, EM | 1 |
| Deetjen, A | 1 |
| Heidland, A | 1 |
| Pangerl, A | 1 |
| Meyer-Sabellek, W | 4 |
| Schaefer, RM | 1 |
| González Maqueda, I | 1 |
| Ruilope, LM | 2 |
| Morgan, T | 3 |
| Biston, P | 1 |
| Van de Borne, P | 1 |
| Mélot, C | 1 |
| Smekens, P | 1 |
| Marinus, W | 1 |
| Degaute, JP | 1 |
| Moser, M | 2 |
| Brooks, DP | 2 |
| Short, BG | 1 |
| Cyronak, MJ | 1 |
| Contino, LC | 2 |
| DiCristo, M | 1 |
| Wang, YX | 1 |
| Ruffolo, RR | 5 |
| Lahera, V | 1 |
| Lessem, JN | 2 |
| Taylor, SH | 4 |
| Storstein, L | 3 |
| van Zwieten, PA | 2 |
| Hayduk, K | 1 |
| Raftery, EB | 4 |
| Hauf-Zachariou, U | 1 |
| Widmann, L | 5 |
| Zülsdorf, B | 1 |
| Hennig, M | 2 |
| Lang, PD | 1 |
| White, WB | 1 |
| Lund-Johansen, P | 9 |
| Omvik, P | 8 |
| Boyle, DA | 2 |
| Venuti, RP | 4 |
| Feuerstein, GZ | 5 |
| Perocchio, M | 1 |
| Gigli, G | 1 |
| Barra, M | 1 |
| Sacchetti, R | 1 |
| Vallebona, A | 1 |
| Rosolen, GA | 1 |
| Orlandi, S | 1 |
| Ostergren, J | 1 |
| Karlberg, BE | 1 |
| Tibblin, G | 1 |
| Weber, K | 2 |
| Bohmeke, T | 2 |
| van der Does, R | 6 |
| Maggi, E | 1 |
| Marchesi, E | 1 |
| Covini, D | 1 |
| Negro, C | 1 |
| Perani, G | 1 |
| Bellomo, G | 1 |
| Sullivan, JM | 1 |
| Barone, FC | 2 |
| Nelson, AH | 3 |
| Ohlstein, EH | 2 |
| Willette, RN | 1 |
| Sealey, JE | 1 |
| Laragh, JH | 1 |
| Campbell, WG | 3 |
| Lithell, H | 1 |
| Andersson, PE | 1 |
| Acampora, R | 2 |
| De Rosa, N | 1 |
| Ziccardi, P | 1 |
| Ragone, R | 1 |
| De Angelis, L | 1 |
| D'Onofrio, F | 2 |
| Antepohl, W | 1 |
| Herzig, S | 1 |
| Böhm, M | 2 |
| Yoshimoto, T | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Naruse, K | 1 |
| Seki, T | 1 |
| Imaki, T | 1 |
| Muraki, T | 1 |
| Matsuda, Y | 1 |
| Demura, H | 1 |
| Albrecht, M | 1 |
| Haustein, KO | 1 |
| Frishman, W | 1 |
| Himmelmann, A | 1 |
| Giunta, R | 1 |
| Coppola, L | 1 |
| Cice, G | 1 |
| Tagliamonte, E | 1 |
| Ferrara, L | 1 |
| Di Benedetto, A | 1 |
| Iacono, A | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Teisman, AC | 1 |
| Pinto, YM | 1 |
| Buikema, H | 1 |
| Flesch, M | 1 |
| Paul, M | 1 |
| van Gilst, WH | 1 |
| Radevski, IV | 1 |
| Valtchanova, SP | 1 |
| Candy, GP | 1 |
| Tshele, EF | 1 |
| Sareli, P | 1 |
| Gehr, TW | 1 |
| Qian, Y | 1 |
| Shusterman, NH | 1 |
| Cleophas, TJ | 1 |
| van der Meulen, J | 1 |
| van de Luit, L | 1 |
| Zwinderman, AH | 1 |
| Cleland, JG | 1 |
| Sack, MN | 1 |
| Harrington, LS | 1 |
| Jonassen, AK | 1 |
| Mjøs, OD | 1 |
| Yellon, DM | 1 |
| Moriguchi, A | 1 |
| Nakagami, H | 1 |
| Kotani, N | 1 |
| Higaki, J | 1 |
| Ogihara, T | 5 |
| Intengan, HD | 1 |
| Schiffrin, EL | 1 |
| Zitta, S | 3 |
| Stoschitzky, K | 3 |
| Zweiker, R | 3 |
| Oettl, K | 1 |
| Reibnegger, G | 1 |
| Holzer, H | 1 |
| Estelberger, W | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Poletti, L | 1 |
| Marasi, G | 1 |
| Mugellini, A | 1 |
| Corradi, L | 1 |
| Cheng, J | 1 |
| Kamiya, K | 1 |
| Kodama, I | 1 |
| Gel'tser, BI | 1 |
| Kotel'nikov, VN | 1 |
| Volkonskaia, OG | 1 |
| Bobyleva, MV | 1 |
| Khitrina, VV | 1 |
| Khludeeva, EA | 1 |
| Wong, VY | 1 |
| Laping, NJ | 1 |
| Olson, BA | 1 |
| Gygielko, E | 1 |
| Barone, F | 1 |
| Klein, W | 2 |
| Gruber, L | 2 |
| Lamprecht, G | 2 |
| Lindner, W | 2 |
| Yang, T | 1 |
| Zhang, Z | 1 |
| Jia, Z | 1 |
| Lin, S | 1 |
| Peng, Y | 1 |
| Asai, T | 1 |
| Kuzuya, M | 1 |
| Koike, A | 1 |
| Kanda, S | 1 |
| Iguchi, A | 1 |
| Koshucharova, G | 1 |
| Lercher, P | 1 |
| Maier, R | 1 |
| Casadei, B | 1 |
| Conway, J | 1 |
| Coats, AJ | 1 |
| Bird, R | 1 |
| Rahn, KH | 2 |
| Franz, IW | 2 |
| Agrawal, B | 1 |
| Wiewel, D | 2 |
| Ketelhut, R | 2 |
| Nordrehaug, JE | 2 |
| Stienen, U | 4 |
| Wendt, T | 1 |
| Masumura, H | 3 |
| Miki, S | 2 |
| Kaifu, Y | 2 |
| Kitajima, W | 1 |
| Senior, R | 1 |
| Müller-Beckmann, B | 5 |
| DasGupta, P | 1 |
| Lahiri, A | 3 |
| Juttmann, JR | 1 |
| de Vries Robles, P | 1 |
| White, W | 1 |
| Cournot, A | 1 |
| Lim, C | 1 |
| Duchier, J | 1 |
| Safar, M | 1 |
| James, IM | 1 |
| Yogendran, L | 1 |
| McLaughlin, K | 1 |
| Munro, C | 1 |
| Sponer, G | 3 |
| Strein, K | 3 |
| Bartsch, W | 3 |
| Eichstaedt, H | 1 |
| Schroeder, RJ | 1 |
| Auffermann, W | 1 |
| Richter, W | 1 |
| Why, HJ | 1 |
| Richardson, PJ | 1 |
| Young, PH | 2 |
| Albergati, F | 1 |
| Paternó, E | 1 |
| Boeri, D | 1 |
| Lombardo, I | 1 |
| Semino, S | 1 |
| Viviani, GL | 1 |
| Adezati, L | 1 |
| Myking, O | 1 |
| Tomita, K | 1 |
| Marumo, F | 1 |
| Ress, KM | 1 |
| Erley, CM | 1 |
| Risler, T | 1 |
| Hall, S | 1 |
| Prescott, RI | 1 |
| Hallman, RJ | 1 |
| Dixon, S | 1 |
| Harvey, RE | 1 |
| Ball, SG | 1 |
| Goto, Y | 4 |
| Tamachi, H | 1 |
| Fusegawa, Y | 1 |
| Nakaya, N | 1 |
| Homma, Y | 2 |
| Mikami, M | 1 |
| Iori, S | 1 |
| Yamazaki, A | 1 |
| Langdon, CG | 1 |
| Baxter, GA | 1 |
| Yuasa, S | 1 |
| Yoshinaga, K | 3 |
| Kamahara, Y | 1 |
| Ikeda, M | 2 |
| Arakawa, K | 2 |
| Iimura, I | 1 |
| Ishii, M | 3 |
| Kokubu, T | 3 |
| Takeda, T | 3 |
| Breckenridge, A | 1 |
| Roberts, DH | 1 |
| Hombach, V | 1 |
| Kochs, M | 1 |
| Höher, M | 1 |
| Eggeling, T | 1 |
| Haerer, W | 1 |
| Wieshammer, S | 1 |
| Schmidt, A | 1 |
| Kling, L | 1 |
| Böhm, E | 1 |
| Martin, U | 1 |
| Borbe, HO | 1 |
| Nagakawa, Y | 1 |
| Akedo, Y | 1 |
| Kaku, S | 1 |
| Orimo, H | 1 |
| Kuriyama, Y | 1 |
| Kyougoku, I | 1 |
| Sawada, T | 1 |
| Morgan, TO | 1 |
| Anderson, A | 2 |
| Cripps, J | 2 |
| Adam, W | 2 |
| Hörrmann, M | 2 |
| Machwirth, M | 3 |
| Seguchi, H | 1 |
| Nakamura, H | 1 |
| Aosaki, N | 1 |
| Mikami, Y | 1 |
| Takahashi, S | 1 |
| Uberbacher, HJ | 1 |
| Dupont, AG | 3 |
| Schoors, DF | 1 |
| Ollivier, JP | 1 |
| Durier, P | 1 |
| Bussiere, JL | 1 |
| Gayet, JL | 1 |
| Krönig, B | 1 |
| Staiger, C | 1 |
| Dehner, R | 1 |
| Ikeda, K | 1 |
| Yamori, Y | 1 |
| Grobecker, H | 1 |
| Schnurr, E | 1 |
| Glocke, M | 1 |
| Kumahara, Y | 2 |
| Iimura, O | 2 |
| Murakami, E | 2 |
| Heber, ME | 2 |
| Brigden, GS | 2 |
| Caruana, MP | 2 |
| Schulte, KL | 2 |
| Distler, A | 2 |
| Gotzen, R | 2 |
| Snowden, R | 1 |
| Butcher, L | 1 |
| Van der Niepen, P | 1 |
| Taeymans, Y | 1 |
| Ingels, M | 1 |
| Piepsz, A | 1 |
| Bossuyt, AM | 1 |
| Block, P | 1 |
| Six, RO | 1 |
| Jonckheer, MH | 1 |
| Vanhaelst, L | 1 |
| Abshagen, U | 1 |
| Tanaka, M | 2 |
| Tanaka, S | 1 |
| Akashi, A | 2 |
| Sampieri, L | 1 |
| Cuspidi, C | 1 |
| Boselli, L | 1 |
| Terzoli, L | 1 |
| Rupoli, L | 1 |
| Zanchetti, A | 1 |
| Mikami, H | 1 |
| Luurila, OJ | 1 |
| Härkönen, R | 1 |
| Hilden, M | 1 |
| Icen, R | 1 |
| Kohvakka, A | 1 |
| Linna, M | 1 |
| Sillanpää, J | 1 |
| Vänskä, O | 1 |
| Lukkala, K | 1 |
| Behr, M | 1 |
| Widimský, J | 1 |
| Lefflerová, K | 1 |
| Ehmer, B | 1 |
| Rudorf, J | 1 |
| Hashimoto, H | 1 |
| Kanda, A | 1 |
| McPhillips, JJ | 1 |
| Schwemer, GT | 1 |
| Scott, DI | 1 |
| Zinny, M | 1 |
| Patterson, D | 1 |
| Rittinghausen, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40m[NCT00347360] | Phase 3 | 654 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Use of Beta-blockers and Risk of New Onset Diabetes[NCT01587638] | 12,336 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients[NCT00827775] | Phase 4 | 55 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans[NCT03016351] | 140 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | |||
| A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Re[NCT00108082] | Phase 3 | 287 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus[NCT00123604] | Phase 4 | 36 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP). (NCT00347360)
Timeframe: Baseline, Week 6.
| Intervention | mmHg (Mean) |
|---|---|
| Lisinopril 10 | -5.79 |
| Lisinopril 20 | -8.11 |
| Lisinopril 40 | -7.37 |
| Carvedilol Controlled Release 20 | -4.40 |
| Carvedilol Controlled Release 40 | -7.61 |
| Carvedilol Controlled Release 80 | -6.52 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -9.29 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -8.57 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -10.19 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -9.36 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -10.96 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -10.37 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -10.93 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -11.09 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -11.92 |
Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP). (NCT00347360)
Timeframe: Baseline, Week 6
| Intervention | mmHg (Mean) |
|---|---|
| Lisinopril 10 | -9.19 |
| Lisinopril 20 | -13.58 |
| Lisinopril 40 | -10.60 |
| Carvedilol Controlled Release 20 | -6.15 |
| Carvedilol Controlled Release 40 | -9.84 |
| Carvedilol Controlled Release 80 | -10.38 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -12.06 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -11.58 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -14.16 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -11.68 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -14.03 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -13.90 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -15.60 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -15.93 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -15.59 |
Trough ABPM was the average across 20-24 hr after dosing for each subject. (NCT00347360)
Timeframe: Baseline, Week 6
| Intervention | mmHg (Mean) |
|---|---|
| Lisinopril 10 | -6.40 |
| Lisinopril 20 | -6.08 |
| Lisinopril 40 | -8.16 |
| Carvedilol Controlled Release 20 | -2.34 |
| Carvedilol Controlled Release 40 | -7.76 |
| Carvedilol Controlled Release 80 | -5.26 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -5.14 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -6.36 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -7.22 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -6.79 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -7.76 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -4.90 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -6.54 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -7.26 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -8.42 |
Trough ABPM was the average across 20-24 hr after dosing for each subject. (NCT00347360)
Timeframe: Baseline, Week 6
| Intervention | mmHg (Mean) |
|---|---|
| Lisinopril 10 | -9.47 |
| Lisinopril 20 | -7.52 |
| Lisinopril 40 | -9.54 |
| Carvedilol Controlled Release 20 | -0.96 |
| Carvedilol Controlled Release 40 | -9.27 |
| Carvedilol Controlled Release 80 | -5.68 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -6.44 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -9.27 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -9.88 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -8.87 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -8.11 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -5.82 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -9.80 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -10.74 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -10.00 |
Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak > 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100. (NCT00347360)
Timeframe: Baseline, Week 6
| Intervention | trough:peak ratio x 100% (Number) |
|---|---|
| Lisinopril 10 | 133.33 |
| Lisinopril 20 | 61.04 |
| Lisinopril 40 | 114.45 |
| Carvedilol Controlled Release 20 | 34.11 |
| Carvedilol Controlled Release 40 | 71.00 |
| Carvedilol Controlled Release 80 | 49.67 |
| Carvedilol Controlled Release 20 Lisinopril 10 | 44.50 |
| Carvedilol Controlled Release 20 Lisinopril 20 | 49.46 |
| Carvedilol Controlled Release 20 Lisinopril 40 | 59.47 |
| Carvedilol Controlled Release 40 Lisinopril 10 | 54.71 |
| Carvedilol Controlled Release 40 Lisinopril 20 | 52.86 |
| Carvedilol Controlled Release 40 Lisinopril 40 | 37.93 |
| Carvedilol Controlled Release 80 Lisinopril 10 | 41.95 |
| Carvedilol Controlled Release 80 Lisinopril 20 | 53.54 |
| Carvedilol Controlled Release 80 Lisinopril 40 | 52.07 |
(NCT00347360)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Lisinopril 10 | 22 |
| Lisinopril 20 | 23 |
| Lisinopril 40 | 27 |
| Carvedilol Controlled Release 20 | 20 |
| Carvedilol Controlled Release 40 | 18 |
| Carvedilol Controlled Release 80 | 17 |
| Carvedilol Controlled Release 20 Lisinopril 10 | 20 |
| Carvedilol Controlled Release 20 Lisinopril 20 | 28 |
| Carvedilol Controlled Release 20 Lisinopril 40 | 25 |
| Carvedilol Controlled Release 40 Lisinopril 10 | 30 |
| Carvedilol Controlled Release 40 Lisinopril 20 | 22 |
| Carvedilol Controlled Release 40 Lisinopril 40 | 27 |
| Carvedilol Controlled Release 80 Lisinopril 10 | 28 |
| Carvedilol Controlled Release 80 Lisinopril 20 | 24 |
| Carvedilol Controlled Release 80 Lisinopril 40 | 28 |
Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP. (NCT00347360)
Timeframe: Baseline, Week 6
| Intervention | mmHg (Mean) |
|---|---|
| Lisinopril 10 | -5.77 |
| Lisinopril 20 | -7.55 |
| Lisinopril 40 | -7.49 |
| Carvedilol Controlled Release 20 | -5.11 |
| Carvedilol Controlled Release 40 | -6.61 |
| Carvedilol Controlled Release 80 | -7.13 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -8.08 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -9.83 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -9.71 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -9.55 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -11.3 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -11.1 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -10.0 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -11.7 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -11.4 |
Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day. (NCT00347360)
Timeframe: Night BP, Baseline, Week 6
| Intervention | mmHg (Mean) | |
|---|---|---|
| Change in Night SBP from Baseline to Week 6 | Change in Night DBP from Baseline to Week 6 | |
| Carvedilol Controlled Release 20 | -4.28 | -3.20 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -10.37 | -8.11 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -9.94 | -7.03 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -12.64 | -9.36 |
| Carvedilol Controlled Release 40 | -7.70 | -6.49 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -10.02 | -8.23 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -11.87 | -9.34 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -11.25 | -9.09 |
| Carvedilol Controlled Release 80 | -7.71 | -5.34 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -12.08 | -8.27 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -14.12 | -9.88 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -13.06 | -10.14 |
| Lisinopril 10 | -9.01 | -5.83 |
| Lisinopril 20 | -11.58 | -6.78 |
| Lisinopril 40 | -10.38 | -7.49 |
Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm. (NCT00347360)
Timeframe: Afternoon BP, Baseline, Week 6
| Intervention | mmHg (Mean) | |
|---|---|---|
| Change in Afternoon SBP from Baseline to Week 6 | Change in Afternoon DBP from Baseline to Week 6 | |
| Carvedilol Controlled Release 20 | -9.69 | -6.27 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -13.96 | -11.28 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -15.54 | -12.04 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -16.38 | -11.59 |
| Carvedilol Controlled Release 40 | -13.34 | -10.12 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -14.51 | -12.18 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -17.97 | -14.03 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -17.82 | -12.54 |
| Carvedilol Controlled Release 80 | -13.76 | -8.38 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -20.91 | -15.12 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -20.46 | -13.87 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -19.36 | -15.02 |
| Lisinopril 10 | -9.68 | -5.62 |
| Lisinopril 20 | -17.21 | -10.25 |
| Lisinopril 40 | -10.53 | -6.67 |
Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon. (NCT00347360)
Timeframe: Morning BP, Baseline, Week 6
| Intervention | mmHg (Mean) | |
|---|---|---|
| Change in Morning SBP from Baseline to Week 6 | Change in Morning DBP from Baseline to Week 6 | |
| Carvedilol Controlled Release 20 | -6.23 | -5.01 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -13.89 | -9.21 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -10.22 | -7.86 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -14.50 | -10.04 |
| Carvedilol Controlled Release 40 | -10.42 | -6.82 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -12.78 | -8.79 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -14.29 | -11.15 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -14.84 | -9.96 |
| Carvedilol Controlled Release 80 | -13.70 | -7.53 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -17.09 | -11.95 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -14.52 | -10.71 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -17.12 | -12.46 |
| Lisinopril 10 | -9.37 | -6.12 |
| Lisinopril 20 | -14.53 | -9.20 |
| Lisinopril 40 | -10.76 | -7.62 |
Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration (NCT00347360)
Timeframe: Baseline, Week 6
| Intervention | mmHg (Mean) | |
|---|---|---|
| Change in sSBP by Cuff from Baseline to Week 6 | Change in sDBP by Cuff from Baseline to Week 6 | |
| Carvedilol Controlled Release 20 | -5.68 | -6.87 |
| Carvedilol Controlled Release 20 Lisinopril 10 | -9.54 | -5.66 |
| Carvedilol Controlled Release 20 Lisinopril 20 | -11.84 | -10.02 |
| Carvedilol Controlled Release 20 Lisinopril 40 | -13.43 | -10.28 |
| Carvedilol Controlled Release 40 | -5.07 | -5.70 |
| Carvedilol Controlled Release 40 Lisinopril 10 | -9.79 | -8.73 |
| Carvedilol Controlled Release 40 Lisinopril 20 | -11.26 | -10.89 |
| Carvedilol Controlled Release 40 Lisinopril 40 | -13.49 | -9.63 |
| Carvedilol Controlled Release 80 | -8.88 | -7.54 |
| Carvedilol Controlled Release 80 Lisinopril 10 | -6.42 | -8.22 |
| Carvedilol Controlled Release 80 Lisinopril 20 | -9.00 | -9.45 |
| Carvedilol Controlled Release 80 Lisinopril 40 | -14.58 | -10.95 |
| Lisinopril 10 | -11.97 | -7.45 |
| Lisinopril 20 | -10.85 | -5.32 |
| Lisinopril 40 | -13.09 | -10.35 |
"ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry~CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry" (NCT00827775)
Timeframe: 12 weeks
| Intervention | % of mononuclear cells (Median) | |
|---|---|---|
| Baseline ALDH bright | Baseline CD34/CD133 endothelial progenitor cells | |
| Control | 0.052 | 0.059 |
"ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry~CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry" (NCT00827775)
Timeframe: 12 weeks
| Intervention | % of mononuclear cells (Median) | |||
|---|---|---|---|---|
| Baseline ALDH bright | Follow up ALDH bright | Baseline CD34/CD133 endothelial progenitor cells | Follow up CD34/CD133 | |
| Intervention | 0.034 | 0.027 | 0.033 | 0.029 |
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later (NCT00827775)
Timeframe: 12 weeks
| Intervention | % dilation from baseline (Mean) |
|---|---|
| Baseline FMD | |
| Control | 1.67 |
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later (NCT00827775)
Timeframe: 12 weeks
| Intervention | % dilation from baseline (Mean) | |
|---|---|---|
| Baseline FMD | Follow Up FMD | |
| Intervention | 1.03 | 1.4 |
LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams (g) (Mean) |
|---|---|
| Carvedilol CR | -13.74 |
| Atenolol | -14.17 |
| Lisinopril | -17.17 |
LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams per meters squared (g/m^2) (Mean) |
|---|---|
| Carvedilol CR | -20.35 |
| Atenolol | -20.06 |
| Lisinopril | -18.48 |
LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams per meters squared (g/m^2) (Mean) |
|---|---|
| Carvedilol CR | -6.34 |
| Atenolol | -6.67 |
| Lisinopril | -7.94 |
LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)
| Intervention | g/m raised to 2.7 (g/(m^2.7)) (Mean) |
|---|---|
| Carvedilol CR | -11.78 |
| Atenolol | -12.51 |
| Lisinopril | -11.61 |
LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | g/m raised to 2.7 (g/(m^2.7)) (Mean) |
|---|---|
| Carvedilol CR | -3.19 |
| Atenolol | -3.37 |
| Lisinopril | -3.98 |
LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams (Mean) |
|---|---|
| Carvedilol CR | -45.76 |
| Atenolol | -40.56 |
| Lisinopril | -38.58 |
Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|---|
| Carvedilol CR | -27.1 |
| Atenolol | -20.1 |
| Lisinopril | -21.5 |
BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) [Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value]. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used
| Intervention | percentage of change (Geometric Mean) |
|---|---|
| Carvedilol CR | 51.7 |
| Atenolol | 48.3 |
| Lisinopril | -39.1 |
CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|---|
| Carvedilol CR | -10.63 |
| Atenolol | -3.22 |
| Lisinopril | 2.70 |
LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume). (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) | |
|---|---|---|
| LV E-volume | LV A-volume | |
| Atenolol | 6.763 | -0.565 |
| Carvedilol CR | 0.364 | -0.513 |
| Lisinopril | -3.406 | 1.088 |
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) | ||
|---|---|---|---|
| LV End Systolic Volume | LV End Diastolic Volume | LV Ejection Fraction | |
| Atenolol | -4.74 | -3.64 | 2.33 |
| Carvedilol CR | -3.38 | -3.07 | 1.03 |
| Lisinopril | -5.34 | -9.37 | 0.63 |
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) | ||
|---|---|---|---|
| LV End Systolic Volume | LV End Diastolic Volume | LV Ejection Fraction | |
| Atenolol | -4.29 | -2.45 | 2.16 |
| Carvedilol CR | -1.44 | -2.86 | 0.08 |
| Lisinopril | -3.04 | -7.45 | -0.01 |
Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | mmHg (millimeters of mercury) (Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Atenolol | -21.12 | -14.05 |
| Carvedilol CR | -21.32 | -12.77 |
| Lisinopril | -22.53 | -11.13 |
Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) | |||
|---|---|---|---|---|
| Total cholesterol | Low-density lipid cholesterol | High-density lipid cholesterol | Triglycerides | |
| Atenolol | -1.3 | -4.0 | -4.7 | 7.1 |
| Carvedilol CR | 0.7 | 0.0 | -4.3 | 11.0 |
| Lisinopril | -1.7 | -2.7 | -1.5 | 6.2 |
Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion. (NCT00123604)
Timeframe: change from baseline to 5 months
| Intervention | percentage of change in dilation (Mean) |
|---|---|
| Carvedilol | 6.2 |
| Metoprolol | 4.1 |
71 reviews available for carvedilol and Blood Pressure, High
| Article | Year |
|---|---|
Beneficial effects of carvedilol modulating potassium channels on the control of glucose.
Topics: Antihypertensive Agents; Blood Glucose; Carbazoles; Cardiovascular Diseases; Carvedilol; Diabetes Me | 2022 |
Carvedilol and bisoprolol as initial therapy for adult hypertension without compelling indications.
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Carvedilol; Humans; Hypertension; Treatment Out | 2019 |
[Arterial hypertension in diabetes mellitus: classical concepts and modern tendencies].
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hyp | 2013 |
β-blockers: a review of their pharmacological and physiological diversity in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Carbazo | 2014 |
[Nephroprotective properties of third-generation beta-adrenoblockers].
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; | 2014 |
[Practice of antihypertensive treatment in diabetic patients with hypertension in Hungary].
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2014 |
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood | 2015 |
Mechanisms and Treatment of Intradialytic Hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Dialysis Solutions; En | 2016 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2016 |
Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Atenolol; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Humans; H | 2008 |
Carvedilol in hypertension treatment.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Comorbidity; Hemodynam | 2008 |
Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cost of Illness; Drug Administration Schedule; | 2008 |
Controlled-release carvedilol.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedi | 2008 |
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2008 |
What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Carve | 2009 |
Role of carvedilol controlled-release in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carvedilol; Delayed-Action Prepara | 2009 |
An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Cardi | 2009 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2009 |
Beta-blockers for hypertension: are they going out of style?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Carve | 2009 |
Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2010 |
The role of Beta-blockers as first-line therapy in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Antihypertensive Agents; Benzopyrans; Bl | 2011 |
The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; | 2012 |
Interdialytic ambulatory blood pressure in patients with intradialytic hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2012 |
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Biomarkers; Carbazoles; Car | 2012 |
Vasodilating versus first-generation β-blockers for cardiovascular protection.
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Benzopyrans; Blood Glucose; Blood | 2012 |
Use of carvedilol in hypertension: an update.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 2012 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Nitric oxide and vascular reactivity in African American patients with hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Black or African American; Brachial Artery; Carba | 2003 |
beta-Blockers in hypertension: is carvedilol different?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Hemodynamics; Humans; | 2004 |
Carvedilol: beta-blockade and beyond.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Clinical Trials as Topic; | 2004 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2006 |
Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Typ | 2006 |
[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine].
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Trials as Topic; Doxazosin; Hemodynamics; | 1995 |
Carvedilol for hypertension.
Topics: Carbazoles; Carvedilol; Humans; Hypertension; Propanolamines | 1995 |
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Carbazoles; Carvedilol; Heart Failure; Hemody | 1993 |
Clinical pharmacokinetics and pharmacodynamics of carvedilol.
Topics: Absorption; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aging; Antihypertensive | 1994 |
Clinical experience with carvedilol.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Carbazoles; Carvedilo | 1993 |
Antihypertensive treatment with a dual-acting beta-blocker in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Diseases; Humans; Hypertension; Pro | 1993 |
Pharmacodynamic profile of carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Free Rad | 1993 |
Carvedilol--clinical experience in arrhythmias.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, | 1993 |
How well are the cardiovascular risk profiles modulated by current beta blockers in hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiovascular Dis | 1993 |
Development of a multiaction beta blocker. Scientific challenges and regulatory needs.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 1993 |
Preclinical and clinical pharmacology of carvedilol.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Trials as Topic; Dogs; Drug Evalu | 1993 |
Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Antioxidants; Arteriosclerosis; Carb | 1995 |
A 1996 update on antihypertensive agents.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Carbazoles; Car | 1996 |
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Carbazoles; Cardiov | 1997 |
Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.
Topics: Adrenergic beta-Antagonists; Antioxidants; Carbazoles; Carvedilol; Heart; Heart Failure; Hemodynamic | 1998 |
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aging; Antioxidants; Blood Pressure; Carbazoles; Carvedilol; Humans; Hy | 1998 |
Hypertension-induced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 1998 |
Carvedilol in the treatment of hypertension--a review of the clinical data base.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Humans; H | 1998 |
[Complex ventricular arrhythmias and carvedilol: efficacy in hemodialyzed uremic patients].
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Humans; Hypertension; Kidney Failure, | 1998 |
Carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 1998 |
Progression from hypertension to heart failure. Mechanisms and management.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Humans; Hyp | 1999 |
Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Antioxi | 2001 |
Clinical experience with dual-acting drugs in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Celipr | 1992 |
Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-R | 1992 |
The role of alpha- and beta-adrenoceptor blockade in antihypertensive treatment.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1992 |
The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output; Carvedilol; Hemodynamics; Humans; Hypertens | 1992 |
The once-daily dose regimen of carvedilol: a meta-analysis approach.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relation | 1992 |
Vasodilatory action of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 1992 |
Hypertension and coronary artery disease: a therapeutic challenge.
Topics: Animals; Blood Pressure; Carbazoles; Carvedilol; Coronary Disease; Humans; Hypertension; Propanolami | 1991 |
Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Extremities; Hemodynam | 1991 |
Hemodynamic profile of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Ventricles; Hemodynamics; Humans | 1990 |
The role of multiple action agents in hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Hemodynamics; | 1990 |
Antihypertensive compounds with combined actions.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Celiprolol; Humans; Hy | 1987 |
A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Forea | 1987 |
Vasodilators in hypertension--a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1985 |
Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetal | 1988 |
118 trials available for carvedilol and Blood Pressure, High
| Article | Year |
|---|---|
A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antihypertensive Agents; Carvedilol; Cross-Over Studi | 2021 |
Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.
Topics: Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2021 |
Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Carvedilol; Case-Control Studies; Cross-Over S | 2020 |
[Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension].
Topics: Adult; Antihypertensive Agents; Benzopyrans; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dru | 2013 |
Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Cross-Over Studies; Double-Bl | 2013 |
Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; C | 2014 |
The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Arterial Pressure; Benzopyrans; Car | 2013 |
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Carbazoles; Carvedilol; Drug Therapy, Combina | 2008 |
[First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)].
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilo | 2008 |
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Press | 2008 |
Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Blood Platelets; Carbazoles | 2009 |
Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy.
Topics: Administration, Sublingual; Adrenergic beta-Antagonists; Aged; Blood Flow Velocity; Blood Pressure; | 2010 |
[Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome].
Topics: Adrenergic alpha-Antagonists; Adult; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Femal | 2009 |
[Drug therapy of diastolic cardiac insufficiency in patients with type 2 diabetes and concomitant essential arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; B | 2009 |
Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antihypertensive Agents; Area Under Curve; B | 2010 |
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Female; | 2010 |
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Drug Therapy, | 2010 |
Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
Topics: Adult; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Carvedilol; Cross-Over Stud | 2011 |
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Topics: Adult; Alleles; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Cytochrome P-450 CY | 2011 |
Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Female; Follow-Up | 2011 |
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Arte | 2011 |
Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Cross | 2012 |
A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Benzoates; Carbazoles; Ca | 2012 |
The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Heart | 2012 |
Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.
Topics: AC133 Antigen; Adult; Aged; Aldehyde Dehydrogenase; Antigens, CD; Antigens, CD34; Antihypertensive A | 2012 |
Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Antioxidants; Benzopyrans; Carbaz | 2012 |
Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiovascular System; Carvedilol; Double-Blind | 2013 |
Aortic elastic properties : effects of carvedilol versus nebivolol.
Topics: Antihypertensive Agents; Aorta; Benzopyrans; Blood Pressure; Carbazoles; Carvedilol; Elastic Modulus | 2013 |
Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocker | 2002 |
Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; C-Reactive P | 2004 |
[Severe heart failure: treatment optimisation and monitoring using plasma NT-proBNP levels--an useful tool in clinical practice].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 2004 |
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2004 |
Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; C | 2005 |
Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients.
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carotid Artery Di | 2005 |
Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Antihypertensive Agents; Antioxidants; C-Reactive Protein; Carba | 2005 |
Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.
Topics: Blood Pressure; Carbazoles; Carvedilol; Female; Heart Rate; Humans; Hypertension; Liver Transplantat | 2005 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
[Antihypertensive activity and effect on parameters of heart rate variability of beta-blockers carvedilol and metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Rate; Humans; Hypertension; Male; | 2005 |
Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzi | 2005 |
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Ag | 2006 |
Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2006 |
Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Area Under Curve; Carbazoles; Carvedilol; | 2006 |
Controlled-release carvedilol in the treatment of essential hypertension.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Delayed-Action Prep | 2006 |
[Comparative efficacy of carvedilol and capoten in the treatment of an uncomplicated hypertensive crisis].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhib | 2006 |
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Canada; Carbazoles; Carvedilol; Delayed-Action Prepar | 2006 |
beta-blocker use and diabetes symptom score: results from the GEMINI study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cognition; Diab | 2007 |
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Double-Blind Metho | 2007 |
Body weight changes with beta-blocker use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Body Weight; C | 2007 |
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2007 |
[Effect of antihypertensive agents from various pharmacological groups on blood pressure reaction during stress-testing. Part I. Comparative characteristics of medications, exerting effect of sympathoadrenal block].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carve | 2008 |
[Effect of antihypertensive drugs of various pharmacological groups on reaction of arterial pressure under conditions of stree testing. Part II. Value of various strategies of potentiation of systemic vasodilatation].
Topics: Acrylates; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2008 |
Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiac Output; Carvedilol; Heart Ra | 1984 |
Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Clinical Trials as Topic; Drug The | 1984 |
Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic | 1984 |
[Use of carvedilol compared to nifedipine in the treatment of mild and moderate essential arterial hypertension].
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Protocols; Del | 1994 |
Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carve | 1995 |
Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; | 1994 |
Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Carba | 1994 |
Carvedilol in the treatment of mild to moderate hypertension: experience with ambulatory blood pressure monitoring.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Diuretics; Drug Therapy, Combinatio | 1994 |
Influence of salt intake on the antihypertensive effect of carvedilol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Diet, | 1993 |
A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.
Topics: Adult; Aged; Antihypertensive Agents; Captopril; Carbazoles; Carvedilol; Cholesterol; Cholesterol, H | 1993 |
Twenty-four-hour blood pressure load as a surrogate end-point in assessing antihypertensive therapy.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Carbazoles; Carvedilol; Human | 1993 |
The preventative effects of vasodilating beta-blockers in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Chronic Disease; Female; | 1996 |
Quality of life in hypertensive patients treated with either carvedilol or enalapril.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Cough; Double-Blind Me | 1996 |
Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood | 1996 |
Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Antioxidants; Autoantibodies; Carbazole | 1996 |
Metabolic effects of carvedilol in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blo | 1997 |
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Argi | 1998 |
Hemodynamic differences between metoprolol and carvedilol in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiac Output; Ca | 1998 |
[Complex ventricular arrhythmias and carvedilol: efficacy in hemodialyzed uremic patients].
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Humans; Hypertension; Kidney Failure, | 1998 |
Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol.
Topics: Adrenergic Antagonists; Adult; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazole | 1998 |
Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Antihypertensive Agents; Black People; Blood Pressure; Carb | 1999 |
Daytime-selective antihypertensive activity of celiprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme | 1999 |
Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dietary Proteins; Female; Fo | 2000 |
Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Hum | 2001 |
[Clinico-functional evaluation of hypotensive effect of carvedilol in elderly patients with mild and moderate arterial hypertension].
Topics: Adrenergic Antagonists; Aged; Antihypertensive Agents; Baroreflex; Carbazoles; Carvedilol; Electroca | 2001 |
[Efficacy of native carvedilol in patients with essential hypertension].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Carbazoles; | 1999 |
Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Carbazoles; Carvedil | 2002 |
Antihypertensive effect of carvedilol: a preliminary dose-response study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors | 1992 |
Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Carbazo | 1992 |
Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Blood Urea Nitrogen; Carbazoles; Carvedilol; Creatinine | 1992 |
Effects of carvedilol on ventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Carv | 1992 |
The once-daily dose regimen of carvedilol: a meta-analysis approach.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relation | 1992 |
Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Del | 1992 |
Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; B | 1992 |
Blood pressure lowering and cerebral blood flow: a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1992 |
A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bloo | 1992 |
Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Female; Human | 1992 |
A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; | 1991 |
A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Humans; Hydroc | 1991 |
Clinical efficacy of carvedilol in severe hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carve | 1991 |
Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Exerci | 1991 |
The use of carvedilol in elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Blood Pressure; Carbazoles | 1990 |
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Choleste | 1990 |
Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Blood Pressure; Carbazoles; C | 1990 |
The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Diure | 1990 |
Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Drug Admin | 1990 |
Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Fema | 1990 |
Effects of carvedilol on renal function.
Topics: Adrenergic beta-Antagonists; Adult; Aldosterone; Blood Pressure; Carbazoles; Carvedilol; Double-Blin | 1990 |
Efficacy and safety of carvedilol in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Body Weight; Carbazoles; Carvedil | 1987 |
The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Circadian Rhythm; | 1987 |
Circadian antihypertensive profile of carvedilol (BM 14190).
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Circadian R | 1987 |
Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Flow Velocity; Blood Pressure; Carbazoles; Carvedilo | 1987 |
Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Blood Pressure; Carbazoles; Carvedilol; Double- | 1987 |
A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Forea | 1987 |
Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Female; Forearm; Heart R | 1987 |
Carvedilol and atenolol once daily in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Carbazoles; Carvedilol; Doubl | 1989 |
Hemodynamic effects of combined beta-adrenoceptor blockade and precapillary vasodilatation in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Female; Hemodynamics; Humans; Hypertensi | 1985 |
Carvedilol for systemic hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Depre | 1987 |
Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Carbazol | 1988 |
Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Chromatography, High Pre | 1988 |
Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as | 1988 |
Follow-up of a method of twenty-four-hour indirect blood pressure monitoring: evaluation of carvedilol, a new antihypertensive agent.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Carbazoles; Carvedilol | 1987 |
128 other studies available for carvedilol and Blood Pressure, High
| Article | Year |
|---|---|
Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Carvedilol; Cohort Studies; Humans; Hydr | 2022 |
Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Humans; Hypertension; Leukocytes, Mononuclear; Timol | 2022 |
Effects of Carvedilol on Blood Pressure, Blood Sugar, and Blood Lipids in Elderly Patients with Refractory Hypertension.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Carvedilol; Humans; Hypertension; Lipi | 2022 |
Carvedilol in patients with cirrhosis and arterial hypertension: two birds with one stone.
Topics: Adrenergic beta-Antagonists; Carvedilol; Humans; Hypertension; Liver Cirrhosis; Propanolamines | 2023 |
Hemolytic Anemia and Thrombocytopenia: How to Treat?
Topics: Amlodipine; Anemia, Hemolytic; Carvedilol; Cocaine; Humans; Hypertension; Male; Medication Adherence | 2020 |
Network-based approach highlighting interplay among anti-hypertensives: target coding-genes: diseases.
Topics: Antihypertensive Agents; Anxiety; Carvedilol; Drug Interactions; Gene Ontology; Heart Diseases; Huma | 2020 |
Better peridialytic blood pressure control using carvedilol in end stage renal disease patients on twice weekly maintenance hemodialysis.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Carvedilol; Female; Humans; Hypert | 2021 |
β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carvedilol; Coronary A | 2021 |
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Carvedilol; D | 2021 |
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Blood Pressure Dete | 2017 |
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carvedilol; Comorbidity; Croatia; Diabetes Mel | 2019 |
β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agent | 2018 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Insights on β-blockers for the treatment of hypertension: A survey of health care practitioners.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black or Af | 2018 |
Smart karaya-locust bean gum hydrogel particles for the treatment of hypertension: Optimization by factorial design and pre-clinical evaluation.
Topics: Animals; Antihypertensive Agents; Carvedilol; Drug Carriers; Drug Design; Drug Liberation; Galactans | 2019 |
The Man Who Saw Things on Carvedilol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Carvedilol; Hallucinations; Hu | 2019 |
Probable carvedilol-induced thrombocytopenia.
Topics: Anticoagulants; Antihypertensive Agents; Antiphospholipid Syndrome; Black or African American; Carba | 2013 |
Editorial comment.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Enalapril; Humans; Hypertension; Male; Propanolamin | 2013 |
Is validation of non-invasive hemodynamic measurement devices actually required?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Carbazoles; Carvedilol; Female | 2014 |
Effects of antihypertensive drugs on central blood pressure: new evidence, more challenges.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Carbazoles; Carvedilol; Female | 2014 |
Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
Topics: Aged; Amides; Antihypertensive Agents; Carbazoles; Carvedilol; Fumarates; Humans; Hypertension; Male | 2014 |
Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Drug Therapy, Combina | 2013 |
Attending rounds: a patient with accelerated hypertension and an atrophic kidney.
Topics: Aged; Amides; Antihypertensive Agents; Atherosclerosis; Atrophy; Blood Pressure; Carbazoles; Carvedi | 2014 |
Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Carbazoles; C | 2014 |
Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; China; Essential Hypertension; Fema | 2014 |
Carvedilol protects the peritubular capillaries and kidney structure in spontaneously hypertensive rats.
Topics: Animals; Capillaries; Carbazoles; Carvedilol; Hypertension; Kidney; Male; Propanolamines; Rats; Rats | 2015 |
Efficacy of carvedilol in reversing hypertension induced by chronic intermittent hypoxia in rats.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Chronic Disease; Hypertension; Hypoxia; Ma | 2015 |
Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
Topics: Aged; Anticoagulants; Antihypertensive Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Cholesta | 2016 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].
Topics: Aged, 80 and over; Angioplasty; Carbazoles; Carvedilol; Combined Modality Therapy; Diagnosis, Differ | 2015 |
Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Angiotens | 2016 |
Transdermal delivery of carvedilol containing glycyrrhizin and chitosan as permeation enhancers: biochemical, biophysical, microscopic and pharmacodynamic evaluation.
Topics: Adjuvants, Pharmaceutic; Administration, Cutaneous; Animals; Antihypertensive Agents; Calorimetry, D | 2008 |
[Heart rate variability dynamics during treatment of arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carb | 2008 |
Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; Blood Pressu | 2009 |
Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats.
Topics: Adrenergic Agonists; Adrenergic alpha-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Bl | 2009 |
[Are mortality or morbidity risks appropriate endpoints for interventional studies in primary or secondary prevention with shared decision-making?].
Topics: Antihypertensive Agents; Biometry; Carbazoles; Carvedilol; Humans; Hypertension; Morbidity; Primary | 2008 |
Effect of Asparagus racemosus extract on transdermal delivery of carvedilol: a mechanistic study.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Asparagus Plant; Blood Pressure; Carbaz | 2009 |
Transdermal delivery of carvedilol in rats: probing the percutaneous permeation enhancement mechanism of soybean extract-chitosan mixture.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Chemistry, Phar | 2009 |
Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2010 |
Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Disease Models, Animal; Do | 2010 |
Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats?
Topics: Adrenergic Antagonists; Animals; Apoptosis; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dise | 2010 |
Combined blockade of β- and α₁-adrenoceptors in left ventricular remodeling induced by hypertension: beneficial or not?
Topics: Adrenergic Antagonists; Animals; Bisoprolol; Carbazoles; Carvedilol; Disease Models, Animal; Humans; | 2010 |
The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Cardiovascular Diseas | 2010 |
[Beta-adrenoblockers for the correction of arterial hypertension in postmenopausal women].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Carbazoles; Carvedilol; Female; Hum | 2010 |
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2010 |
Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age of Onset; Aged; Antihypertensive Agents; Carbazoles; Carvedi | 2011 |
Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and ove | 2011 |
Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats.
Topics: Adiposity; Adrenergic Antagonists; Animals; Body Weight; Caffeine; Carbazoles; Carvedilol; Catechola | 2012 |
Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Fructose; Heart Rate; Hype | 2012 |
Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 2012 |
Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Chemical Analysis; Carbazoles; Carvedilo | 2012 |
[Elevated augmentation index].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Bisoprolol; Blood Pressure; Carbazole | 2012 |
Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Carbazoles; Carvedilol; Databases, Fact | 2012 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
Activation of protein kinase C and nicotinamide adenine dinucleotide phosphate oxidase in leukocytes of spontaneously hypertensive rats.
Topics: Adrenergic Antagonists; Animals; Antihypertensive Agents; Antioxidants; Blotting, Western; Carbazole | 2003 |
Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Pressure Determination; Carbazoles; Carv | 2004 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Bisoprolol; Blood Pressure; Calc | 2004 |
Contribution of sympathetic nervous system activity during administration of carvedilol in rats with dilated cardiomyopathy.
Topics: Animals; Blood Pressure; Body Weight; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response | 2003 |
Pre-weaning carvedilol treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Animals, Suckling; Blood Pressur | 2004 |
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antioxidants; Carbazoles; Carvedilol; Cell Death; Cell Hypoxia; Cells, Cultured | 2004 |
Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2004 |
The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Biomarkers; Blood Pressure; Carba | 2004 |
Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients.
Topics: Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Humans; Hypertension; Inflammation; O | 2005 |
Carvedilol, metoprolol, and insulin resistance.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Humans; Hypertension; In | 2005 |
The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients.
Topics: Absorption; Adrenergic beta-Antagonists; ATP Binding Cassette Transporter, Subfamily B, Member 1; Ca | 2005 |
Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Atenolol; Biomarkers; Blood Pressure; Blottin | 2006 |
Effect of matrine and carvedilol on collagen and MMPs activity of hypertrophy myocardium induced by pressure overload.
Topics: Alkaloids; Animals; Carbazoles; Cardiomegaly; Carvedilol; Cells, Cultured; Collagen; Endomyocardial | 2006 |
[Efficiency and safety of carvedilol treatment in high risk hypertensive patients].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diab | 2006 |
Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2006 |
Oxidative stress: a potentially important new marker in renal transplantation.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Gene | 2006 |
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Delayed-Action Prepara | 2006 |
Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Bandages; Carbazoles; Carvedilol; Diffu | 2007 |
Pharmacological washout for the correct evaluation of the head-up tilt testing.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Diagnostic Errors; Drug Therapy, Combination; | 2008 |
Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Autonomic Nervous System; Carbazoles; Cardiomyopathy, Dilated; Carvedil | 2007 |
[Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
[Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Blood Pressure Mon | 2007 |
Beta-blockers in the treatment of hypertension: new data, new directions.
Topics: Adrenergic beta-Antagonists; Aged; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; Cau | 2008 |
Refining the Logic of Antihypertensive Therapy: An International Symposium on Carvedilol. Paris, France, October 19, 1990.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Humans; Hypertension; Propanolamines | 1993 |
Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Urea Nitrogen; Captopril; Carbazoles; Ca | 1993 |
Hypertension in the spectrum of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiovascular Diseases; Carvedilol; Humans; Hyper | 1993 |
Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Free Radical Scavengers; | 1993 |
Carvedilol in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Carba | 1993 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium- | 1993 |
[Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 1996 |
Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Wei | 1996 |
[Carvedilol].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; | 1997 |
Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Carbazoles | 1998 |
The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Visco | 1997 |
Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Carbazoles; | 1998 |
Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; An | 1998 |
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blo | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats.
Topics: Acyl-CoA Dehydrogenase; Animals; Antihypertensive Agents; Carbazoles; Cardiomegaly; Carvedilol; Coen | 2000 |
Contribution of cardiovascular hypersensitivity to orthostatic hypertension and the extreme dipper phenomenon.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aged; Antihypertensive Agents; Blood Pressure; | 2000 |
Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Endothelium, | 2000 |
[Beta blocker therapy for elderly hypertensive patients].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Hemodynamics; Humans; Hypertension; Propa | 2000 |
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2000 |
[New indications for beta blockers. Cave hypertension focus/heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; D | 2000 |
[The taboo topic of sexual activity in hypertensive patients. Pioneer study from Pavia proves: potency is not impaired].
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Ere | 2001 |
Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Collagen Type I; Dieta | 2001 |
Unpredicted lack of effect of exercise on plasma concentrations of carvedilol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Chromatography, High P | 2002 |
[Effects of carvedilol on the hemodynamics and its tolerance in elderly patients].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Carb | 2002 |
Carvedilol: a new approach to antihypertensive therapy. Proceedings from International Symposium on Carvedilol. Berlin, March 14-17, 1991.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Humans; Hypertension; Propanolamines | 1992 |
Long-term hemodynamic effects of antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Echocardiograph | 1992 |
Multiple action agents in cardiovascular therapy. Satellite symposium to the 5th European Meeting on Hypertension. Milan, Italy, June 11, 1991.
Topics: Carbazoles; Carvedilol; Humans; Hypertension; Propanolamines; Vasodilator Agents | 1992 |
Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; C | 1992 |
Regression of left ventricular hypertrophy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiomegaly; Carvedilol; Echocardiogr | 1992 |
Effect of carvedilol on left ventricular function and mass in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carve | 1992 |
Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressu | 1992 |
Effect of long-term carvedilol therapy on renal function in essential hypertension.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Blood Ur | 1992 |
Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Exerci | 1992 |
Effects of carvedilol on serum lipids in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blo | 1991 |
Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1991 |
Pharmacological characteristics of the stereoisomers of carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Blood Pressure; | 1990 |
Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Blood Viscosity; Carbazoles; Cardiac Output; Caro | 1990 |
Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carbon Dioxide; Carvedilol; Cerebrovascular | 1990 |
Effects of carvedilol on serum lipids in hypertensive and normotensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; Chole | 1990 |
Adrenaline in cardiovascular diseases--effect of beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Cardiovascular Diseases; Carvedilo | 1990 |
Pharmacokinetics of carvedilol in older and younger patients.
Topics: Adult; Aged; Aging; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response R | 1990 |
Carvedilol for systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ambulatory Care; Blood Pressure; Carbazoles; Carvedilol; C | 1987 |
Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; | 1987 |
Studies on the antihypertensive properties of carvedilol, a compound with beta-blocking and vasodilating effects.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Cardiac Outp | 1987 |
Resting and postexercise hemodynamic effects of carvedilol, a beta-adrenergic blocker and precapillary vasodilator in hypertensive patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Fe | 1987 |
[Clinical application of adrenoceptor blockers in the treatment of hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertens | 1989 |
[Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block].
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiomegaly; Carvedilol; Chronic Di | 1986 |
Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Decerebrate State; Dos | 1988 |
Dose-effect relationship of carvedilol in essential hypertension. An open study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Rela | 1988 |